<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Nitric oxide for respiratory failure in infants born at or near term - Barrington, KJ - 2017 | Cochrane Library</title> <meta content="Nitric oxide for respiratory failure in infants born at or near term - Barrington, KJ - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000399.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Nitric oxide for respiratory failure in infants born at or near term - Barrington, KJ - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000399.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000399.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Nitric oxide for respiratory failure in infants born at or near term" name="citation_title"/> <meta content="Keith J Barrington" name="citation_author"/> <meta content="CHU Ste‐Justine" name="citation_author_institution"/> <meta content="keith.barrington@umontreal.ca" name="citation_author_email"/> <meta content="Neil Finer" name="citation_author"/> <meta content="University of California San Diego" name="citation_author_institution"/> <meta content="Thomas Pennaforte" name="citation_author"/> <meta content="Université de Montréal" name="citation_author_institution"/> <meta content="Gabriel Altit" name="citation_author"/> <meta content="Universite de Montreal ‐ CHU Sainte‐Justine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD000399.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/01/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000399.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000399.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000399.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Extracorporeal Membrane Oxygenation; Hernia, Diaphragmatic [complications]; High-Frequency Ventilation; Nitric Oxide [administration &amp; dosage, *therapeutic use]; Randomized Controlled Trials as Topic; Respiratory Insufficiency [*drug therapy, mortality]; Term Birth; Vasodilator Agents [administration &amp; dosage, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000399.pub3&amp;doi=10.1002/14651858.CD000399.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="jxlIh5Me";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000399\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000399\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000399.pub3",title:"Nitric oxide for respiratory failure in infants born at or near term",firstPublishedDate:"Jan 5, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000399.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000399.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000399.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000399.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000399.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000399.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000399.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000399.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000399.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000399.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6122 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000399.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-sec-0083"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-sec-0080"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/appendices#CD000399-sec-0088"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/table_n/CD000399StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/table_n/CD000399StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Nitric oxide for respiratory failure in infants born at or near term</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/information#CD000399-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Keith J Barrington</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/information#CD000399-cr-0003">Neil Finer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/information#CD000399-cr-0004">Thomas Pennaforte</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000399.pub3/information#CD000399-cr-0005">Gabriel Altit</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/information/en#CD000399-sec-0093">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 January 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000399.pub3">https://doi.org/10.1002/14651858.CD000399.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000399-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000399-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000399-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000399-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000399-abs-0001" lang="en"> <section id="CD000399-sec-0001"> <h3 class="title" id="CD000399-sec-0001">Background</h3> <p>Nitric oxide (NO) is a major endogenous regulator of vascular tone. Inhaled nitric oxide (iNO) gas has been investigated as treatment for persistent pulmonary hypertension of the newborn. </p> </section> <section id="CD000399-sec-0002"> <h3 class="title" id="CD000399-sec-0002">Objectives</h3> <p>To determine whether treatment of hypoxaemic term and near‐term newborn infants with iNO improves oxygenation and reduces rate of death and use of extracorporeal membrane oxygenation (ECMO), or affects long‐term neurodevelopmental outcomes. </p> </section> <section id="CD000399-sec-0003"> <h3 class="title" id="CD000399-sec-0003">Search methods</h3> <p>We used the standard search strategy of the Cochrane Neonatal Review Group to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 1), MEDLINE via PubMed (1966 to January 2016), Embase (1980 to January 2016) and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to January 2016). We searched clinical trials databases, conference proceedings and reference lists of retrieved articles for randomised controlled trials and quasi‐randomised trials. We contacted the principal investigators of studies published as abstracts to ascertain the necessary information. </p> </section> <section id="CD000399-sec-0004"> <h3 class="title" id="CD000399-sec-0004">Selection criteria</h3> <p>Randomised studies of iNO in term and near‐term infants with hypoxic respiratory failure, with clinically relevant outcomes, including death, use of ECMO and oxygenation. </p> </section> <section id="CD000399-sec-0005"> <h3 class="title" id="CD000399-sec-0005">Data collection and analysis</h3> <p>We analysed trial reports to assess methodological quality using the criteria of the Cochrane Neonatal Review Group. We tabulated mortality, oxygenation, short‐term clinical outcomes (particularly use of ECMO) and long‐term developmental outcomes. </p> <p>Statistics: For categorical outcomes, we calculated typical estimates for risk ratios and risk differences. For continuous variables, we calculated typical estimates for weighted mean differences. We used 95% confidence intervals and assumed a fixed‐effect model for meta‐analysis. </p> </section> <section id="CD000399-sec-0006"> <h3 class="title" id="CD000399-sec-0006">Main results</h3> <p>We found 17 eligible randomised controlled studies that included term and near‐term infants with hypoxia. </p> <p>Ten trials compared iNO versus control (placebo or standard care without iNO) in infants with moderate or severe severity of illness scores (<a href="http://Ninos 1996" target="_blank">Ninos 1996</a>; <a href="http://Roberts 1996" target="_blank">Roberts 1996</a>; <a href="http://Wessel 1996" target="_blank">Wessel 1996</a>; <a href="http://Davidson 1997" target="_blank">Davidson 1997</a>; <a href="http://Ninos 1997" target="_blank">Ninos 1997</a>; <a href="http://Mercier 1998" target="_blank">Mercier 1998</a>; <a href="http://Christou 2000" target="_blank">Christou 2000</a>; <a href="http://Clark 2000" target="_blank">Clark 2000</a>; <a href="http://INNOVO 2007" target="_blank">INNOVO 2007</a>; <a href="http://Liu 2008" target="_blank">Liu 2008</a>). <a href="http://Mercier 1998" target="_blank">Mercier 1998</a> compared iNO versus control but allowed back‐up treatment with iNO for infants who continued to satisfy the same criteria for severity of illness after two hours. This trial enrolled both preterm and term infants but reported most results separately for the two groups. <a href="http://Ninos 1997" target="_blank">Ninos 1997</a> studied only infants with congenital diaphragmatic hernia. </p> <p>One trial compared iNO versus high‐frequency ventilation (<a href="http://Kinsella 1997" target="_blank">Kinsella 1997</a>). </p> <p>Six trials enrolled infants with moderate severity of illness scores (oxygenation index (OI) or alveolar‐arterial oxygen difference (A‐aDO<sub>2</sub>)) and randomised them to immediate iNO treatment or iNO treatment only after deterioration to more severe criteria (<a href="http://Barefield 1996" target="_blank">Barefield 1996</a>; <a href="http://Day 1996" target="_blank">Day 1996</a>; <a href="http://Sadiq 1998" target="_blank">Sadiq 1998</a>; <a href="http://Cornfield 1999" target="_blank">Cornfield 1999</a>; <a href="http://Konduri 2004" target="_blank">Konduri 2004</a>; <a href="http://Gonzalez 2010" target="_blank">Gonzalez 2010</a>). </p> <p>Inhaled nitric oxide appears to have improved outcomes in hypoxaemic term and near‐term infants by reducing the incidence of the combined endpoint of death or use of ECMO (high‐quality evidence). This reduction was due to a reduction in use of ECMO (with number needed to treat for an additional beneficial outcome (NNTB) of 5.3); mortality was not affected. Oxygenation was improved in approximately 50% of infants receiving iNO. The OI was decreased by a (weighted) mean of 15.1 within 30 to 60 minutes after the start of therapy, and partial pressure of arterial oxygen (PaO<sub>2</sub>) was increased by a mean of 53 mmHg. Whether infants had clear echocardiographic evidence of persistent pulmonary hypertension of the newborn (PPHN) did not appear to affect response to iNO. Outcomes of infants with diaphragmatic hernia were not improved; outcomes were slightly, but not significantly, worse with iNO (moderate‐quality evidence). </p> <p>Infants who received iNO at less severe criteria did not have better clinical outcomes than those who were enrolled but received treatment only if their condition deteriorated. Fewer of the babies who received iNO early satisfied late treatment criteria, showing that earlier iNO reduced progression of the disease but did not further decrease mortality nor the need for ECMO (moderate‐quality evidence). Incidence of disability, incidence of deafness and infant development scores were all similar between tested survivors who received iNO and those who did not. </p> </section> <section id="CD000399-sec-0007"> <h3 class="title" id="CD000399-sec-0007">Authors' conclusions</h3> <p>Inhaled nitric oxide is effective at an initial concentration of 20 ppm for term and near‐term infants with hypoxic respiratory failure who do not have a diaphragmatic hernia. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000399-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000399-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000399-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000399-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000399-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000399-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000399-abs-0003" lang="en"> <h3>Nitric oxide for respiratory failure in infants born at or near term</h3> <p><b>Review question</b>: Is inhaled nitric oxide gas, in addition to standard therapy, beneficial for babies born at full term who have lung disease leading to low levels of oxygen in the blood? Specifically, does it reduce the death rate or the number of babies who require highly invasive ECMO treatment? </p> <p><b>Background</b>: Nitric oxide is a naturally occurring molecule that relaxes blood vessels and is active in the lungs when mixed with the gases that a patient is breathing. </p> <p><b>Study characteristics</b>: In a search updated to February 2016, review authors identified a total of 17 studies for inclusion in the review. Most of the results reported in this review were obtained from 10 studies of moderate to high quality, which compared inhaled nitric oxide (iNO) versus standard therapy without iNO. Six studies compared iNO started when babies were less sick against waiting to see if they deteriorated, then treating them later. These studies were smaller, and only one was a high‐quality trial. </p> <p><b>Key results</b>: Inhaled nitric oxide is safe and can help some full‐term babies with respiratory failure who have not responded to other methods of support. Inhaled nitric oxide increases levels of oxygen in babies' blood, and babies are more likely to survive without needing ECMO, a highly invasive therapy with many complications. Unfortunately, benefits of iNO are not clear in babies whose respiratory failure is due to a diaphragmatic hernia. Inhaled nitric oxide has shown no short‐term or long‐term adverse effects. No signs suggest that iNO given earlier is more beneficial or results in more babies treated, and the number who die or who need ECMO is not significantly reduced. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000399-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000399-sec-0083"></div> <h3 class="title" id="CD000399-sec-0084">Implications for practice</h3> <section id="CD000399-sec-0084"> <p>On the basis of currently available information, iNO has been established as effective therapy for near‐term and term infants with hypoxic respiratory failure unresponsive to other therapy, with the possible exclusion of infants with congenital diaphragmatic hernia. Its use reduces the need for ECMO (with number needed to treat for an additional beneficial outcome (NNTB) of 5.3), and it appears to be the only selective pulmonary vasodilator for which proof of efficacy is available. </p> <p>Lack of effect on systemic haemodynamics, coupled with relative safety of administration when appropriately monitored, and lack of significant longer‐term neurodevelopmental sequelae support the use of iNO in preference to other vasodilators. </p> <p>It appears to be appropriate to institute therapy for those who are severely ill (with OI ≥ 25, or PaO<sub>2</sub> &lt; 100 mmHg in 100% oxygen); commencing therapy earlier does not appear to further reduce ECMO requirements or mortality (however, some uncertainty surrounds this, as confidence intervals of the RR are very wide (0.61 to 1.24)). Instituting therapy at lower severity of illness criteria may prevent progression to higher disease severity. </p> </section> <h3 class="title" id="CD000399-sec-0085">Implications for research</h3> <section id="CD000399-sec-0085"> <p>Additional studies with untreated control groups in term and near‐term infants with hypoxic respiratory failure would not be ethically acceptable. </p> <p>Comparative trials with other active agents, or with different doses of iNO, may be valuable. Indeed, the minimal effective dose remains unclear. <a href="./references#CD000399-bbs2-0055" title="FinerNN , BarringtonKJ . Nitric oxide in respiratory failure in full‐term and nearly full‐term newborn infants (Cochrane Review). Cochrane Database of Systematic Reviews2001, Issue 2. [DOI: 10.1002/14651858.CD000399.pub2] ">Finer 2001</a> suggested that starting treatment at 2 ppm was as effective as starting treatment at higher concentrations, whereas <a href="./references#CD000399-bbs2-0004" title="CornfieldDN , MaynardRC , deRegnierRA , GuiangSF3rd , BarbatoJE , MillaCE . Randomized, controlled trial of low‐dose inhaled nitric oxide in the treatment of term and near‐term infants with respiratory failure and pulmonary hypertension. Pediatrics1999;104:1089‐94. ">Cornfield 1999</a> suggested that starting treatment at 2 ppm was not effective in preventing deterioration. This discrepancy warrants further investigation by an adequately powered study. </p> <p>Moreover, treating at less severe criteria for poor oxygenation has not been shown to improve mortality or ECMO requirements, or other reported clinical outcomes, compared with waiting to see whether the patient's condition deteriorates. However, substantial uncertainty remains regarding effects on death or ECMO, with 95% confidence intervals including the possibility of a 40% reduction in death or ECMO, or a 25% increase. Also, earlier treatment may prevent disease progression, and long‐term outcomes could be affected by preventing more severe illness. This should be further investigated. </p> <p>Finally, other unanswered questions include the following: Does pretreatment with surfactant improve response to iNO in humans (as it appears to in some animal models)? Is iNO safer and more effective than other vasodilators delivered by inhalation such as inhaled prostacyclin? </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000399-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000399-sec-0015"></div> <div class="table" id="CD000399-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Inhaled NO compared with control for respiratory failure in infants born at or near term</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Inhaled NO compared with control for respiratory failure in infants born at or near term</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> respiratory failure in infants born at or near term<br/> <b>Setting:</b> neonatal intensive care units<br/> <b>Intervention:</b> inhaled NO<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inhaled NO</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death or use of ECMO; studies that did not allow back‐up use of iNO in controls</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/> (0.57 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>859<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>540 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>356 per 1000<br/> (308 to 416) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death or use of ECMO; infants with diaphragmatic hernia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.09<br/> (0.95 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>870 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>948 per 1000<br/> (826 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death before hospital discharge; studies that did not allow back‐up use of iNO in controls </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.60 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>860<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/> (72 to 157) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death before hospital discharge; infants with diaphragmatic hernia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.20<br/> (0.74 to 1.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>391 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1000<br/> (290 to 767) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Use of ECMO before hospital discharge; studies that did not allow back‐up use of iNO in controls </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.60<br/> (0.50 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>815<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>514 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1000<br/> (257 to 365) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Use of ECMO before hospital discharge; infants with diaphragmatic hernia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.27<br/> (1.00 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>674 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>856 per 1000<br/> (674 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurodevelopmental disability at 18 to 24 months among survivors</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.66 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>301<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1000<br/> (175 to 382) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; OR: odds ratio; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to the estimate of effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Small numbers of participants studied. </p> <p><sup>b</sup>Subgroup of participants from only 2 trials evaluated. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000399-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Inhaled NO at moderate compared with severe criteria for illness severity in respiratory failure among infants born at or near term</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Inhaled NO at moderate compared with severe criteria for illness severity in respiratory failure among infants born at or near term</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants born at or near term in respiratory failure<br/> <b>Setting:</b> neonatal intensive care units<br/> <b>Intervention:</b> inhaled NO at moderate criteria for illness severity (earlier iNO)<br/> <b>Comparison:</b> inhaled NO at severe criteria for illness severity (later iNO) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inhaled NO at severe criteria for illness severity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Inhaled NO at moderate criteria for illness severity</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death or requirement for ECMO</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.62 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>495<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000<br/> (119 to 244) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death before hospital discharge</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.69<br/> (0.38 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>495<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000<br/> (38 to 126) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Use of ECMO before hospital discharge</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/> (0.66 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>439<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>146 per 1000<br/> (95 to 222) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression to severe criteria</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/> (0.55 to 0.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>512<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>595 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>392 per 1000<br/> (327 to 470) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurodevelopmental disability at 18 to 24 months among survivors</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.74 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>234<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000<br/> (183 to 431) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; OR: odds ratio; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to the estimate of effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Highly variable risk ratio. </p> <p><sup>b</sup>Very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000399-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000399-sec-0016"></div> <section id="CD000399-sec-0017"> <h3 class="title" id="CD000399-sec-0017">Description of the condition</h3> <p>Persistent pulmonary hypertension of the newborn (PPHN) is an important cause of cardiorespiratory failure in the near‐term neonate (&gt; 34 weeks), as a primary condition of neonatal maladaptation or secondary to other diseases such as hyaline membrane disease (HMD), meconium aspiration, infection and congenital diaphragmatic hernia (CDH). A review of the Oxford Database of Perinatal Trials performed in 1996, which included PPHN as an outcome, showed that at that time, no single randomised controlled trial (RCT) had demonstrated that PPHN could be prevented by any perinatal intervention. PPHN is a common underlying factor among infants who qualify for treatment with extracorporeal membrane oxygenation (ECMO). </p> <p>Before inhaled nitric oxide (iNO) was available, conventional therapy involved paralysis, sedation and induction of alkalosis by hyperventilation and bicarbonate. None of these therapies were proven by prospective randomised trials to reduce mortality nor the need for ECMO. In addition, no clinically evaluated selective pulmonary vasodilator was free of systemic side effects. </p> </section> <section id="CD000399-sec-0018"> <h3 class="title" id="CD000399-sec-0018">Description of the intervention</h3> <p>Addition of low concentrations of nitric oxide gas to the inhaled gas mixture.</p> </section> <section id="CD000399-sec-0019"> <h3 class="title" id="CD000399-sec-0019">How the intervention might work</h3> <p>Regulation of vascular muscle tone at the cellular level occurs, in part, via nitric oxide (NO). Nitric oxide is generated enzymatically by one of three NO synthases from L‐arginine. NO activates guanyl cyclase by binding to its heme component, leading to the production of cyclic guanosine monophosphate (cGMP), which leads to relaxation of vascular smooth muscle. </p> <p>Abman and coworkers (<a href="./references#CD000399-bbs2-0020" title="AbmanSH , ChatfieldBA , HallSL , McMurtryIF . Role of endothelium‐derived relaxing factor during transition of pulmonary circulation at birth. American Journal of Physiology1990;259:H1921‐7. ">Abman 1990</a>) showed, in the late gestation ovine fetus, that inhibition of NO production caused foetal pulmonary and systemic hypertension with attenuation of the rise in pulmonary blood flow at delivery. They also demonstrated that inhibition of NO formation impeded the pulmonary vasodilation produced by ventilation, increasing oxygen tension and shear stress (<a href="./references#CD000399-bbs2-0023" title="CornfieldDN , ChatfieldBA , McQuestonJA , McMurtryIF , AbmanSH . Effects of birth‐related stimuli on L‐arginine‐dependent pulmonary vasodilation in ovine fetus. American Journal of Physiology1992;262:H1474‐81. ">Cornfield 1992</a>), and that inhalation of NO by the ovine foetus caused sustained and selective pulmonary vasodilation (<a href="./references#CD000399-bbs2-0038" title="KinsellaJP , McQuestonJA , RosenbergAA , AbmanSH . Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation. American Journal of Physiology1992;263:H875‐80. ">Kinsella 1992a</a>). </p> <p>In newborn mammals, several models of pulmonary hypertension are reversed by iNO (<a href="./references#CD000399-bbs2-0028" title="FratacciMD , FrostellCG , ChenTY , WainJC , RobinsonDR , ZapolWM . Inhaled nitric oxide ‐ A selective pulmonary vasodilator of heparin‐protamine vasoconstriction in sheep. Anesthesiology1991;75:990‐9. ">Fratacci 1991</a>; <a href="./references#CD000399-bbs2-0029" title="FrostellC , FratacciMD , WainJC , JonesR , ZapolWM . Inhaled nitric oxide ‐ A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation1991;83:2038‐47. ">Frostell 1991</a>; <a href="./references#CD000399-bbs2-0049" title="RobertsJDJr , ChenT‐Y . Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb. Circulation Research1993;72:246. ">Roberts 1993</a>; <a href="./references#CD000399-bbs2-0026" title="EtchesPC , FinerNN , BarringtonKJ , GrahamAJ , ChanWKY . Nitric oxide reverses pulmonary hypertension in the newborn piglet. Pediatric Research1994;35:15‐9. ">Etches 1994</a>). None of these studies reported an effect on systemic vascular resistance. </p> <p>In adults with pulmonary hypertension, the initial observation by Higenbottam and coworkers (<a href="./references#CD000399-bbs2-0034" title='HigenbottamT , Pepke‐ZabaJ , ScottJ , WollmanP , CouttsC , WallworkJ . Inhaled "endothelium‐derived relaxing factor" (EDRF) in primary hypertension (PPH). American Review of Respiratory Disease1988;137:A107. '>Higenbottam 1988</a>) that iNO decreases pulmonary vascular resistance was confirmed by Pepke‐Zaba and coworkers (<a href="./references#CD000399-bbs2-0044" title="Pepke‐ZabaJ , HigenbottamTW , Dinh‐XuanAT , StoneD , WallworkJ . Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet1991;338:1173‐4. ">Pepke‐Zaba 1991</a>), who showed that iNO (40 ppm) reduced pulmonary hypertension with no change in systemic vascular resistance. In adults with acute respiratory distress syndrome, Rossaint and coworkers (<a href="./references#CD000399-bbs2-0051" title="RossaintR , FalkeKJ , LopezF , SlamaK , PisonU , ZapolWM . Inhaled nitric oxide for the adult respiratory distress syndrome. New England Journal of Medicine1993;328:399‐405. ">Rossaint 1993</a>) showed a reduction in pulmonary arterial pressure and a decrease in intrapulmonary shunting within 40 minutes of inhalation of NO. In these patients, improvement in oxygenation was due largely to improved ventilation/perfusion matching. </p> </section> <section id="CD000399-sec-0020"> <h3 class="title" id="CD000399-sec-0020">Why it is important to do this review</h3> <p>Two uncontrolled reports in neonates with PPHN from separate groups working in Denver (<a href="./references#CD000399-bbs2-0039" title="KinsellaJP , NeishSR , ShafferE , AbmanSH . Low‐dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet1992;340:819‐20. ">Kinsella 1992b</a>) and Boston (<a href="./references#CD000399-bbs2-0048" title="RobertsJD , PolanerDM , LangP , ZapolWM . Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet1992;340:818‐9. ">Roberts 1992</a>) indicated that iNO rapidly produced a significant improvement in preductal oxygen saturation, with no detectable toxicity. The Boston group (<a href="./references#CD000399-bbs2-0048" title="RobertsJD , PolanerDM , LangP , ZapolWM . Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet1992;340:818‐9. ">Roberts 1992</a>) revealed that concentrations of 80 ppm of iNO were required to achieve a response, whereas the Denver group (<a href="./references#CD000399-bbs2-0039" title="KinsellaJP , NeishSR , ShafferE , AbmanSH . Low‐dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet1992;340:819‐20. ">Kinsella 1992b</a>) observed beneficial effects with only 10 to 20 ppm. This latter group reported on nine additional infants treated with iNO, eight of whom showed a sustained beneficial response (<a href="./references#CD000399-bbs2-0040" title="KinsellaJP , NeishSR , IvyDD , ShafferE , AbmanSH . Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. Journal of Pediatrics1993;123:103‐8. ">Kinsella 1993</a>). Finer and coworkers conducted a prospective evaluation of the dose response to iNO in infants referred for possible ECMO therapy (<a href="./references#CD000399-bbs2-0027" title="FinerNN , EtchesPC , KamstraB , TierneyAJ , PeliowskiA , RyanCA . Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. Journal of Pediatrics1994;124:302‐8. ">Finer 1994</a>). Inhalation of NO was associated with significant improvements in partial pressure of arterial oxygen (PaO<sub>2</sub>) and decreases in alveolar‐arterial oxygen difference (A‐aDO<sub>2</sub>) and oxygenation index (OI) among 14 of 21 studied infants. Investigators noted no difference in response between 5 ppm and higher concentrations. </p> <p>Preliminary evidence led to prospective randomised controlled clinical trials conducted to evaluate the role of iNO in infants with respiratory failure. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000399-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000399-sec-0021"></div> <p>To determine whether treatment of hypoxaemic term and near‐term newborn infants with iNO improves oxygenation and reduces rate of death and use of extracorporeal membrane oxygenation (ECMO), or affects long‐term neurodevelopmental outcomes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000399-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000399-sec-0022"></div> <section id="CD000399-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000399-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included only randomised prospective clinical trials.</p> </section> <section id="CD000399-sec-0025"> <h4 class="title">Types of participants</h4> <p>Participants were newborn infants (&lt; 1 month of age) with hypoxaemia suspected to be due to lung disease, pulmonary hypertension with right‐to‐left shunting or both. We included only studies in term and near‐term infants (&gt; 34 weeks' gestation). In all studies, investigators made an effort to exclude infants with intracardiac shunting due to structural congenital heart disease. As infants with congenital diaphragmatic hernia (CDH) may respond differently from other near‐term infants (from preliminary data), as far as possible results for these infants were evaluated separately. </p> </section> <section id="CD000399-sec-0026"> <h4 class="title">Types of interventions</h4> <p>Studies compared administration of iNO gas versus control ‐ no gas or placebo gas.</p> </section> <section id="CD000399-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD000399-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD000399-list-0001"> <li> <p>Death or use of ECMO</p> </li> <li> <p>Death before hospital discharge</p> </li> <li> <p>Use of ECMO before hospital discharge</p> </li> </ol> </p> </section> <section id="CD000399-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD000399-list-0002"> <li> <p>Improvement in oxygenation (as a dichotomous variable) within 30 to 60 minutes</p> </li> <li> <p>Effects on oxygenation index after 30 to 60 minutes of therapy (both absolute values and change from baseline) </p> </li> <li> <p>Effects on partial pressure of arterial oxygen (PaO<sub>2</sub>) after 30 to 60 minutes of therapy (both absolute values and change from baseline) </p> </li> <li> <p>Neurodevelopmental disability at 18 to 24 months</p> </li> <li> <p>Cerebral palsy</p> </li> <li> <p>Cognitive impairment at 18 to 24 months</p> </li> <li> <p>Deafness</p> </li> </ol> </p> <section id="CD000399-sec-0030"> <h6 class="title">Outcomes added post hoc</h6> <p> <ol id="CD000399-list-0003"> <li> <p>Change in oxygenation index after treatment</p> </li> <li> <p>Change in PaO<sub>2</sub> after treatment </p> </li> <li> <p>Chronic lung disease</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD000399-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <p>We used Cochrane criteria and standard methods and those of the Cochrane Neonatal Review Group (see <a href="http://neonatal.cochrane.org/resources-review-authors" target="_blank">the Cochrane Neonatal Group search strategy for specialized register</a>). </p> <section id="CD000399-sec-0032"> <h4 class="title">Electronic searches</h4> <p>For the 1998 review, we used standard methods of the Neonatal Collaborative Review Group. We performed the first MEDLINE search in March 1997, using the search engine 'Melvyl medline plus' and the following search terms: 'key word=nitric', and 'subject heading = infant, newborn'. </p> <p>For the 2016 update, we conducted a comprehensive search that included the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 1) in the Cochrane Library; MEDLINE via PubMed (1966 to January 2016); Embase (1980 to January 2016); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to January 2016), using the following search terms: (Nitric OR Nitrix Oxide), plus database‐specific limiters for RCTs and neonates (see <a href="./appendices#CD000399-sec-0089">Appendix 1</a> for the full search strategies for each database). We applied no language restrictions. </p> </section> <section id="CD000399-sec-0033"> <h4 class="title">Searching other resources</h4> <p>For the 1998 review, we searched Society for Pediatric Research meeting abstracts on diskette for 1995, 1996 and 1997, using the terms 'control, controls or controlled' and 'nitric or NO'. </p> <p>For the 2016 update, we searched clinical trials registries for ongoing and recently completed trials (<a href="https://www.clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; the World Health Organization International Trials Registry and Platform (<a href="http://www.whoint/ictrp/search/en/" target="_blank">www.whoint/ictrp/search/en/</a>); and <a href="http://www.isrctn.com/" target="_blank">the ISRCTN Registry</a>). We also searched conference abstracts from the Pediatric Academic Societies (PAS) and the European Society for Paediatric Research (ESPR). We carried out searches in Abstracts 2 View (2000 to 2014) and <i>Pediatric Research</i>. </p> </section> </section> <section id="CD000399-sec-0034"> <h3 class="title" id="CD000399-sec-0034">Data collection and analysis</h3> <p>For each included study, we collected information regarding method of randomisation, blinding, drug intervention, stratification and whether the trial was a single‐centre or multi‐centre study. We noted information regarding trial participants, including gestational age criteria, birth weight criteria and other inclusion or exclusion criteria. We analysed information on clinical outcomes, including death or use of ECMO, death before hospital discharge, use of ECMO before hospital discharge, improvement in oxygenation (as a dichotomous variable) within 30 to 60 minutes, effects on OI after 30 to 60 minutes of therapy (both absolute values and changes from baseline), effects on PaO<sub>2</sub> after 30 to 60 minutes of therapy (both absolute values and changes from baseline), neurodevelopmental disability at 18 to 24 months, cerebral palsy, cognitive impairment at 18 to 24 months and deafness. </p> <section id="CD000399-sec-0035"> <h4 class="title">Selection of studies</h4> <p>We included all randomised and quasi‐randomised controlled trials fulfilling the selection criteria described in the previous section. All review authors reviewed results of the search, separately selected studies for inclusion and resolved disagreements by discussion. </p> </section> <section id="CD000399-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>KB, TP and GA extracted, assessed and coded all data for each study, for studies newly added to this version of the review, using the same categories as were used in the previous version. We replaced any standard error of the mean reported with the corresponding standard deviation and resolved disagreements by discussion. For each study, one review author (KB) entered final data into Review Manager (<a href="./references#CD000399-bbs2-0047" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and the other review authors (NF, TP, GA) checked the data. All review authors reviewed the protocol, analysis and draft manuscript. </p> </section> <section id="CD000399-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We employed standard methods of the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/NEONATAL/sect0-meta.html" target="_blank">Cochrane Neonatal Group</a>. We assessed methodological quality of studies by using the following key criteria: allocation concealment (blinding of randomisation), blinding of intervention, completeness of follow‐up and blinding of outcome measurement/assessment. We assessed each criterion as introducing high, low or unclear risk. We included this information in the <a href="./references#CD000399-sec-0099" title="">Characteristics of included studies</a> table. </p> <p>In addition, review authors independently assessed risk of bias for each study by using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000399-bbs2-0035" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>We assessed methodological quality of studies by using the following criteria.</p> <p> <ol id="CD000399-list-0004"> <li> <p>Sequence generation (evaluating possible selection bias). For each included study, we described the method used to generate the allocation sequence as adequate (any truly random process, e.g. random number table; computer random number generator), inadequate (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number; or an unverifiable process, e.g. coin toss) or unclear. </p> </li> <li> <p>Allocation concealment (evaluating possible selection bias). For each included study, we described the method used to conceal the allocation sequence as adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes), inadequate (open random allocation; unsealed or non‐opaque envelopes; alternation; date of birth) or unclear. </p> </li> <li> <p>Blinding (evaluating possible performance bias). For each included study, we described methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes, and we assessed methods as adequate, inadequate or unclear for participants; adequate, inadequate or unclear for study personnel; and adequate, inadequate or unclear for outcome assessors. </p> </li> <li> <p>Incomplete outcome data (evaluating possible attrition bias through withdrawals, drop‐outs, protocol deviations). For each included study and for each outcome, we described the completeness of data including attrition and exclusions from analysis. We stated whether attrition and exclusions were reported, numbers included in the analysis at each stage (compared with total randomised participants) and reasons for attrition or exclusion when reported, and whether missing data were balanced across groups or were related to outcomes. We assessed methods as adequate (&lt; 20% missing data), inadequate (≥ 20% missing data) or unclear. </p> </li> <li> <p>Selective reporting bias. For each included study for which the protocol was available (through trials registers), we investigated the possibility of selective outcome reporting bias and reported what we found. We assessed methods as adequate (when it was clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review had been reported), inadequate (when not all of the study's prespecified outcomes had been reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; or study failed to include results of a key outcome that would have been expected to have been reported) or unclear. </p> </li> <li> <p>Other sources of bias. We noted other possible sources of bias (e.g. whether a potential source of bias was related to the specific study design, whether the trial was stopped early owing to some data‐dependent process). We assessed whether each study was free of other problems that could put it at risk of bias as yes, no or unclear. </p> </li> <li> <p>Funding sources. For each study, we attempted to determine the nature and, if possible, the role of the funding source. Using published or registered protocols and the final publication of the main trial results, we determined whether funds for the trial were obtained from local agencies (e.g. research groups, hospital foundations, university funds), charitable sources (local, national or international foundations), government agencies or industry sources. If potential funding conflicts of interest were evident (particularly with industry funding), we evaluated the role of the funding source. We determined that when funding was received entirely from industry, studies were at high risk of bias. In cases of funding received in part from industry sources, we evaluated risk of bias according to the apparent role of the funding source. </p> </li> </ol> </p> </section> <section id="CD000399-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>We performed statistical analyses using Review Manager 5 software (<a href="./references#CD000399-bbs2-0047" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We analysed categorical data using risk ratio (RR) and risk difference (RD). For statistically significant outcomes, we calculated the number needed to treat for an additional beneficial outcome (NNTB) or the number needed to treat for an additional harmful outcome (NNTH). We analysed continuous data by using weighted mean difference (WMD) and standardised mean difference (SMD). We reported 95% confidence intervals (CIs) for all estimates. </p> </section> <section id="CD000399-sec-0039"> <h4 class="title">Assessment of heterogeneity</h4> <p>We estimated treatment effects reported by individual trials and examined heterogeneity among trials by inspecting forest plots and quantifying the impact of heterogeneity using the I² statistic. We graded the degree of heterogeneity as less than 25% (no heterogeneity), 25% to 49% (low heterogeneity), 50% to 75% (moderate heterogeneity) or greater than 75% (substantial heterogeneity). If we noted statistical heterogeneity (I² &gt; 50%), we explored possible causes (e.g. differences in study quality, participants, intervention regimens or outcome assessments). </p> </section> <section id="CD000399-sec-0040"> <h4 class="title">Data synthesis</h4> <p>If we identified multiple studies and thought they were sufficiently similar, we performed meta‐analysis by using RevMan version 5.3, as supplied by Cochrane. For categorical outcomes, we calculated typical estimates of RR and RD, each with its 95% CI, and for continuous outcomes, WMD or a summary estimate for SMD, each with its 95% CI. We used a fixed‐effect model for meta‐analysis. When we judged meta‐analysis to be inappropriate, we analysed and interpreted separately subgroups of individual trials that were very similar. </p> <section id="CD000399-sec-0041"> <h5 class="title">Quality of evidence</h5> <p>We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, as outlined in the <i>GRADE Handbook</i> (<a href="./references#CD000399-bbs2-0052" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GWG . GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. www.guidelinedevelopment.org/handbookUpdated October 2013. ">Schünemann 2013</a>), to assess the quality of evidence for the following (clinically relevant) outcomes: survival without the need for ECMO (or its converse ‐ death or use of ECMO) and the two components of that outcome ‐ death (before hospital discharge) and use of ECMO. The long‐term outcome that we considered important was evaluation of neurodevelopmental disability at 18 to 24 months (components of which were cerebral palsy, cognitive impairment and deafness). </p> <p>Two review authors (KB and TP) independently assessed the quality of the evidence for each of the outcomes above. We considered evidence from RCTs as high quality but downgraded evidence one level for serious (or two levels for very serious) limitations on the basis of the following: design (risk of bias), consistency across studies, directness of evidence, precision of estimates and presence of publication bias. We used the <a href="./references#CD000399-bbs2-0030" title="McMaster University. GRADEpro [www.gradepro.org]. Ontario: McMaster University, 2014. ">GRADEpro</a> Guideline Development Tool to create a ‘Summary of findings’ table to report the quality of the evidence. </p> <p>The GRADE approach results in an assessment of the quality of a body of evidence according to one of four grades. </p> <p> <ol id="CD000399-list-0005"> <li> <p>High: We are very confident that the true effect lies close to the estimate of effect.</p> </li> <li> <p>Moderate: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different. </p> </li> <li> <p>Low: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect. </p> </li> <li> <p>Very low: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ol> </p> </section> </section> <section id="CD000399-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The major subgroups that we analysed included trials that compared iNO versus no iNO and trials that compared immediate nitric oxide treatment upon enrolment in the trial versus selective treatment only when the infant's condition deteriorated, to satisfy rescue treatment criteria. We considered separately the unique study comparing high‐frequency ventilation versus iNO (<a href="./references#CD000399-bbs2-0009" title="KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariE , ClarkRH , et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency ventilation in severe persistent pulmonary hypertension of the newborn. Pediatric Research1996;39:222A. KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariEE , MayockDE , et al. Randomized, multicenter trial of inhaled nitric oxide and high‐frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. Journal of Pediatrics1997;131:55‐62. ">Kinsella 1997</a>) and did not include this study in the meta‐analysis. </p> <p>Among studies that compared iNO versus control, we examined three subgroups: trials that did not allow iNO in the control group; the one study (<a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a>) that allowed iNO at the physician's discretion (with no specific criteria) after a relatively brief two‐hour period; and trials that enrolled participants with diaphragmatic hernia. </p> <p>We used the I<sup>2</sup> statistic for investigation of heterogeneity in each subgroup. </p> </section> <section id="CD000399-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>For major outcomes, we performed sensitivity analysis by running the meta‐analysis both while including and while excluding studies at higher risk of bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000399-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000399-sec-0044"></div> <section id="CD000399-sec-0045"> <h3 class="title">Description of studies</h3> <section id="CD000399-sec-0046"> <h4 class="title">Results of the search</h4> <p>The previous version of this review identified 14 randomised controlled trials. Updated searches revealed 652 records after duplicates were removed; after screening, review authors identified three new RCTs for inclusion in the review (<a href="#CD000399-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD000399-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram: review update." data-id="CD000399-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> </div> </section> <section id="CD000399-sec-0047"> <h4 class="title">Included studies</h4> <p>In all, we identified 17 RCTs including term and near‐term infants with hypoxaemic respiratory failure (<a href="./references#CD000399-bbs2-0001" title="BarefieldES , KarkeVA , PhillipsJB , CarloWA . Inhaled nitric oxide in term infants with hypoxemic respiratory failure. Journal of Pediatrics1996;129:279‐86. BarefieldES , KarkeVA , PhillipsJB , CarloWA . Randomized, controlled trial of inhaled NO in ECMO candidates. Pediatric Research1995;37:195A. ">Barefield 1996</a>; <a href="./references#CD000399-bbs2-0006" title="DayRW , LynchJM . Acute hemodynamic and blood gas effects of inhaled nitric oxide in newborns with lung disease and pulmonary hypertension. Pediatric Research1996;39:330A. DayRW , LynchJM , WhiteKS , WardRM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics1996;98:698‐705. ">Day 1996</a>; <a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>; <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>; <a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a>; <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>; <a href="./references#CD000399-bbs2-0009" title="KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariE , ClarkRH , et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency ventilation in severe persistent pulmonary hypertension of the newborn. Pediatric Research1996;39:222A. KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariEE , MayockDE , et al. Randomized, multicenter trial of inhaled nitric oxide and high‐frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. Journal of Pediatrics1997;131:55‐62. ">Kinsella 1997</a>; <a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a>; <a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a>; <a href="./references#CD000399-bbs2-0016" title="SadiqFH , Illinois Multicenter Trial. Treatment of persistent pulmonary hypertension of the newborn with nitric oxide: a randomized trial. Pediatric Research1998;43:192A. SadiqHF , MantychG , BenawraRS , DevaskarUP , HockerJR . Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. Journal of Perinatology2003;23:98‐103. ">Sadiq 1998</a>; <a href="./references#CD000399-bbs2-0004" title="CornfieldDN , MaynardRC , deRegnierRA , GuiangSF3rd , BarbatoJE , MillaCE . Randomized, controlled trial of low‐dose inhaled nitric oxide in the treatment of term and near‐term infants with respiratory failure and pulmonary hypertension. Pediatrics1999;104:1089‐94. ">Cornfield 1999</a>; <a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a>; <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a>; <a href="./references#CD000399-bbs2-0010" title="KonduriGG , SolimanoA , SokolGM , SingerJ , EhrenkranzRA , SinghalN , et al. Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near‐term newborn infants with hypoxic respiratory failure. Pediatrics2004;113(3 Pt 1):559‐64. KonduriGG , VohrB , RobertsonC , SokolGM , SolimanoA , SingerJ , et al. Early inhaled nitric oxide therapy for term and near‐term newborn infants with hypoxic respiratory failure: neurodevelopmental follow‐up. Journal of Pediatrics2007;150(3):235‐40.e1. ">Konduri 2004</a>; <a href="./references#CD000399-bbs2-0008" title="FieldD , ElbourneD , HardyP , FentonAC , AhluwaliaJ , HallidayHL , et al. INNOVO Trial Collaborating Group. Neonatal ventilation with inhaled nitric oxide vs. ventilatory support without inhaled nitric oxide for infants with severe respiratory failure born at or near term: the INNOVO multicentre randomised controlled trial. Neonatology2007;91(2):73‐82. ">INNOVO 2007</a>; <a href="./references#CD000399-bbs2-0011" title="LiuCQ , MaL , TangLM , HeXJ , WeiSF , WangSX , et al. A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2008;46(3):224‐8. ">Liu 2008</a>; <a href="./references#CD000399-bbs2-0007" title="GonzalezA , FabresJ , D'ApremontI , UrcelayG , AvacaM , GandolfiC , et al. Randomized controlled trial of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension. Journal of Perinatology2010;30(6):420‐4. ">Gonzalez 2010</a>). </p> <p>Ten of these trials (<a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>; <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>; <a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a>; <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>; <a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a>; <a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a>; <a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a>; <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a>; <a href="./references#CD000399-bbs2-0008" title="FieldD , ElbourneD , HardyP , FentonAC , AhluwaliaJ , HallidayHL , et al. INNOVO Trial Collaborating Group. Neonatal ventilation with inhaled nitric oxide vs. ventilatory support without inhaled nitric oxide for infants with severe respiratory failure born at or near term: the INNOVO multicentre randomised controlled trial. Neonatology2007;91(2):73‐82. ">INNOVO 2007</a>; <a href="./references#CD000399-bbs2-0011" title="LiuCQ , MaL , TangLM , HeXJ , WeiSF , WangSX , et al. A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2008;46(3):224‐8. ">Liu 2008</a>) compared iNO versus control (placebo or standard care without iNO in infants with moderate or severe severity of illness scores), and 10 did not allow use of iNO in control groups. One trial (<a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a>) allowed treatment of both control and intervention participants after 2 hours of iNO at the physician's discretion, without clear criteria for treatment initiation in the control group. We therefore included this trial in group 1 but as a separate subgroup. Two trials applied other restrictions to eligibility criteria: One study enrolled only infants with diaphragmatic hernia (<a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a>) and compared iNO versus placebo, while not allowing open‐label iNO. The other study (<a href="./references#CD000399-bbs2-0011" title="LiuCQ , MaL , TangLM , HeXJ , WeiSF , WangSX , et al. A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2008;46(3):224‐8. ">Liu 2008</a>) included only infants with meconium aspiration and compared iNO versus no iNO (for this trial, no back‐up ECMO was available). </p> <p>One trial randomised infants to iNO or high‐frequency ventilation (<a href="./references#CD000399-bbs2-0009" title="KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariE , ClarkRH , et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency ventilation in severe persistent pulmonary hypertension of the newborn. Pediatric Research1996;39:222A. KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariEE , MayockDE , et al. Randomized, multicenter trial of inhaled nitric oxide and high‐frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. Journal of Pediatrics1997;131:55‐62. ">Kinsella 1997</a>), crossed participants over to the other treatment in case of failure, then combined treatments if the cross‐over was not successful. </p> <p>Six of these trials (<a href="./references#CD000399-bbs2-0001" title="BarefieldES , KarkeVA , PhillipsJB , CarloWA . Inhaled nitric oxide in term infants with hypoxemic respiratory failure. Journal of Pediatrics1996;129:279‐86. BarefieldES , KarkeVA , PhillipsJB , CarloWA . Randomized, controlled trial of inhaled NO in ECMO candidates. Pediatric Research1995;37:195A. ">Barefield 1996</a>; <a href="./references#CD000399-bbs2-0006" title="DayRW , LynchJM . Acute hemodynamic and blood gas effects of inhaled nitric oxide in newborns with lung disease and pulmonary hypertension. Pediatric Research1996;39:330A. DayRW , LynchJM , WhiteKS , WardRM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics1996;98:698‐705. ">Day 1996</a>; <a href="./references#CD000399-bbs2-0016" title="SadiqFH , Illinois Multicenter Trial. Treatment of persistent pulmonary hypertension of the newborn with nitric oxide: a randomized trial. Pediatric Research1998;43:192A. SadiqHF , MantychG , BenawraRS , DevaskarUP , HockerJR . Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. Journal of Perinatology2003;23:98‐103. ">Sadiq 1998</a>; <a href="./references#CD000399-bbs2-0004" title="CornfieldDN , MaynardRC , deRegnierRA , GuiangSF3rd , BarbatoJE , MillaCE . Randomized, controlled trial of low‐dose inhaled nitric oxide in the treatment of term and near‐term infants with respiratory failure and pulmonary hypertension. Pediatrics1999;104:1089‐94. ">Cornfield 1999</a>; <a href="./references#CD000399-bbs2-0010" title="KonduriGG , SolimanoA , SokolGM , SingerJ , EhrenkranzRA , SinghalN , et al. Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near‐term newborn infants with hypoxic respiratory failure. Pediatrics2004;113(3 Pt 1):559‐64. KonduriGG , VohrB , RobertsonC , SokolGM , SolimanoA , SingerJ , et al. Early inhaled nitric oxide therapy for term and near‐term newborn infants with hypoxic respiratory failure: neurodevelopmental follow‐up. Journal of Pediatrics2007;150(3):235‐40.e1. ">Konduri 2004</a>; <a href="./references#CD000399-bbs2-0007" title="GonzalezA , FabresJ , D'ApremontI , UrcelayG , AvacaM , GandolfiC , et al. Randomized controlled trial of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension. Journal of Perinatology2010;30(6):420‐4. ">Gonzalez 2010</a>) randomised infants with moderate severity of illness scores (defined by OI or A‐aDO<sub>2</sub>) to an intervention group that received immediate iNO and compared them with controls who were treated without iNO unless they deteriorated to more serious severity scores, in which case iNO was used. </p> <p>These three groups of trials are investigating different questions: 'Is iNO preferable to no treatment?' 'Is iNO preferable to high‐frequency ventilation, or is the combination better?' 'Is early iNO preferable to later iNO?' Therefore, we divided the trials post hoc into the three groups. </p> <p>One of the above studies enrolled infants of any gestational age but reported most descriptive and outcome data separately for preterm (&lt; 33 weeks' gestation) and near‐term (≥ 33 weeks') babies (<a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a>). These studies varied in size from n = 17 (<a href="./references#CD000399-bbs2-0001" title="BarefieldES , KarkeVA , PhillipsJB , CarloWA . Inhaled nitric oxide in term infants with hypoxemic respiratory failure. Journal of Pediatrics1996;129:279‐86. BarefieldES , KarkeVA , PhillipsJB , CarloWA . Randomized, controlled trial of inhaled NO in ECMO candidates. Pediatric Research1995;37:195A. ">Barefield 1996</a>) to n = 235 (<a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>). Eligibility criteria have been reasonably homogeneous; some studies excluded infants with pulmonary hypoplasia, some excluded infants with pulmonary hypoplasia of any cause and others specifically excluded only those with congenital diaphragmatic hernia (<a href="./references#CD000399-bbs2-0001" title="BarefieldES , KarkeVA , PhillipsJB , CarloWA . Inhaled nitric oxide in term infants with hypoxemic respiratory failure. Journal of Pediatrics1996;129:279‐86. BarefieldES , KarkeVA , PhillipsJB , CarloWA . Randomized, controlled trial of inhaled NO in ECMO candidates. Pediatric Research1995;37:195A. ">Barefield 1996</a>; <a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>; <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>; <a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a>; <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>; <a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a>; <a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a>; <a href="./references#CD000399-bbs2-0010" title="KonduriGG , SolimanoA , SokolGM , SingerJ , EhrenkranzRA , SinghalN , et al. Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near‐term newborn infants with hypoxic respiratory failure. Pediatrics2004;113(3 Pt 1):559‐64. KonduriGG , VohrB , RobertsonC , SokolGM , SolimanoA , SingerJ , et al. Early inhaled nitric oxide therapy for term and near‐term newborn infants with hypoxic respiratory failure: neurodevelopmental follow‐up. Journal of Pediatrics2007;150(3):235‐40.e1. ">Konduri 2004</a>), whereas the remaining studies included infants with these conditions (<a href="./references#CD000399-bbs2-0006" title="DayRW , LynchJM . Acute hemodynamic and blood gas effects of inhaled nitric oxide in newborns with lung disease and pulmonary hypertension. Pediatric Research1996;39:330A. DayRW , LynchJM , WhiteKS , WardRM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics1996;98:698‐705. ">Day 1996</a>; <a href="./references#CD000399-bbs2-0009" title="KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariE , ClarkRH , et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency ventilation in severe persistent pulmonary hypertension of the newborn. Pediatric Research1996;39:222A. KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariEE , MayockDE , et al. Randomized, multicenter trial of inhaled nitric oxide and high‐frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. Journal of Pediatrics1997;131:55‐62. ">Kinsella 1997</a>; <a href="./references#CD000399-bbs2-0016" title="SadiqFH , Illinois Multicenter Trial. Treatment of persistent pulmonary hypertension of the newborn with nitric oxide: a randomized trial. Pediatric Research1998;43:192A. SadiqHF , MantychG , BenawraRS , DevaskarUP , HockerJR . Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. Journal of Perinatology2003;23:98‐103. ">Sadiq 1998</a>; <a href="./references#CD000399-bbs2-0004" title="CornfieldDN , MaynardRC , deRegnierRA , GuiangSF3rd , BarbatoJE , MillaCE . Randomized, controlled trial of low‐dose inhaled nitric oxide in the treatment of term and near‐term infants with respiratory failure and pulmonary hypertension. Pediatrics1999;104:1089‐94. ">Cornfield 1999</a>; <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a>). The Ninos group ran a parallel RCT of infants with congenital diaphragmatic hernia (<a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a>). Most studies limited participants to near‐term infants (≥ 34 weeks: <a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>; <a href="./references#CD000399-bbs2-0009" title="KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariE , ClarkRH , et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency ventilation in severe persistent pulmonary hypertension of the newborn. Pediatric Research1996;39:222A. KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariEE , MayockDE , et al. Randomized, multicenter trial of inhaled nitric oxide and high‐frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. Journal of Pediatrics1997;131:55‐62. ">Kinsella 1997</a>; <a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a>; <a href="./references#CD000399-bbs2-0004" title="CornfieldDN , MaynardRC , deRegnierRA , GuiangSF3rd , BarbatoJE , MillaCE . Randomized, controlled trial of low‐dose inhaled nitric oxide in the treatment of term and near‐term infants with respiratory failure and pulmonary hypertension. Pediatrics1999;104:1089‐94. ">Cornfield 1999</a>; <a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a>; <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a>; ≥ 35 weeks: <a href="./references#CD000399-bbs2-0001" title="BarefieldES , KarkeVA , PhillipsJB , CarloWA . Inhaled nitric oxide in term infants with hypoxemic respiratory failure. Journal of Pediatrics1996;129:279‐86. BarefieldES , KarkeVA , PhillipsJB , CarloWA . Randomized, controlled trial of inhaled NO in ECMO candidates. Pediatric Research1995;37:195A. ">Barefield 1996</a>; 'full term': <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>; <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>), but <a href="./references#CD000399-bbs2-0006" title="DayRW , LynchJM . Acute hemodynamic and blood gas effects of inhaled nitric oxide in newborns with lung disease and pulmonary hypertension. Pediatric Research1996;39:330A. DayRW , LynchJM , WhiteKS , WardRM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics1996;98:698‐705. ">Day 1996</a> included preterm infants (five of 50 participants). </p> <p>Hypoxaemic respiratory failure was required for entry into each of these studies, but exact criteria differed and are noted in the <a href="./references#CD000399-sec-0099" title="">Characteristics of included studies</a> table. </p> <p>Many, but not all, of the studies (<a href="./references#CD000399-bbs2-0006" title="DayRW , LynchJM . Acute hemodynamic and blood gas effects of inhaled nitric oxide in newborns with lung disease and pulmonary hypertension. Pediatric Research1996;39:330A. DayRW , LynchJM , WhiteKS , WardRM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics1996;98:698‐705. ">Day 1996</a>; <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>; <a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a>; <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>; <a href="./references#CD000399-bbs2-0009" title="KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariE , ClarkRH , et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency ventilation in severe persistent pulmonary hypertension of the newborn. Pediatric Research1996;39:222A. KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariEE , MayockDE , et al. Randomized, multicenter trial of inhaled nitric oxide and high‐frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. Journal of Pediatrics1997;131:55‐62. ">Kinsella 1997</a>; <a href="./references#CD000399-bbs2-0016" title="SadiqFH , Illinois Multicenter Trial. Treatment of persistent pulmonary hypertension of the newborn with nitric oxide: a randomized trial. Pediatric Research1998;43:192A. SadiqHF , MantychG , BenawraRS , DevaskarUP , HockerJR . Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. Journal of Perinatology2003;23:98‐103. ">Sadiq 1998</a>; <a href="./references#CD000399-bbs2-0004" title="CornfieldDN , MaynardRC , deRegnierRA , GuiangSF3rd , BarbatoJE , MillaCE . Randomized, controlled trial of low‐dose inhaled nitric oxide in the treatment of term and near‐term infants with respiratory failure and pulmonary hypertension. Pediatrics1999;104:1089‐94. ">Cornfield 1999</a>; <a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a>) also required echocardiographic evidence of PPHN. <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a> required clinical or echocardiographic evidence of PPHN, and <a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a> required no evidence of PPHN. </p> <p>Many studies reported data regarding short‐term effects on oxygenation as percentage or absolute change in PaO<sub>2</sub> and OI. Data for all percentages, absolute changes and absolute values were available to us only for the <a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a> study. Other studies provided results in one way or another. </p> <section id="CD000399-sec-0048"> <h5 class="title">Trials comparing iNO versus control (no iNO)</h5> <p><a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a> was a multi‐centre trial that included participants 14 days of age or younger without congenital structural heart disease. Although all infants in this trial received an echocardiogram before randomisation, an echocardiographic diagnosis of PPHN was not an inclusion criterion for this trial, as it was for many of the other trials herein reported. Infants were randomly assigned to receive 20 ppm of iNO or placebo; in this study, the placebo gas was 100% oxygen. The primary hypothesis was that administration of iNO to such infants would reduce the risk of death or the need for ECMO by 120 days from 50% in control infants to 30% in infants receiving iNO. This study encouraged full aggressive conventional therapy including high‐frequency ventilation provided by centres experienced in its use, use of a bovine surfactant as well as maintenance of arterial blood pressure above 45 mmHg, induction of alkalosis (target pH 7.45 to 7.60) with encouragement for use of sedation and/or paralysis and vasopressors and volume expansion as necessary to maintain blood pressure. The external data safety monitoring committee recommended termination of the trial after the second planned review of data revealed that the trial had reached the predetermined boundary of statistical significance, at which time 235 infants (121 controls and 114 infants in the iNO group) had been enrolled. These two groups were well matched for their clinical characteristics and blood gas values and were nearly identical in the use of support treatments at the time of randomisation. Approximately 55% of infants were receiving high‐frequency ventilation at the time of randomisation, and approximately 72% had received surfactant before randomisation. More than 90% of all infants had received volume and vasopressor support, neuromuscular blockade and sedation before randomisation. </p> <p>The <a href="./references#CD000399-bbs2-0043" title="Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the neonatal inhaled nitric oxide study group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 2000</a> publication presents follow‐up of survivors of the two Ninos studies who underwent comprehensive neurodevelopmental assessment at 18 to 24 months of age. A secondary hypothesis of the original study was that administration of iNO would lead to no increase in neurodevelopmental disability at 18 to 24 months. Of 235 infants enrolled, 36 died, and 176 of the 199 survivors were assessed at follow‐up: 88 control infants and 85 iNO infants. In addition, this study included survivors of the parallel trial of infants with congenital diaphragmatic hernia (<a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a>). Among the original 53 enrolled infants, 29 were survivors and follow‐up was available for eight of 13 iNO survivors and for 14 of 16 control infants. Survivors were well matched for their neonatal characteristics. Investigators performed structured neurological examinations and hearing tests, and blinded assessors most often assigned Bayley Scales of Infant Development (BSID) scores. </p> <p><a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a> conducted a multi‐centre trial including infants who had fraction of inspired oxygen (FiO<sub>2</sub>) of 1.0 and postductal PaO<sub>2</sub> of 55 mmHg or less on two consecutive determinations 30 minutes apart. Researchers excluded infants who had polycythaemia (hematocrit ≥ 70%) or uncorrected hypotension (defined as mean aortic blood pressure &lt; 40 mmHg) or an unevacuated pneumothorax. They also excluded infants who had received treatment with high‐frequency oscillatory ventilation or jet ventilation and included infants who had previously received surfactant without sustained improvement in oxygenation. All infants had FiO<sub>2</sub> reduced to 0.9 and were enrolled if they maintained PaO<sub>2</sub> greater than 85% of their previous baseline. An interim analysis after 50 participants were enrolled demonstrated that iNO increased systemic oxygenation significantly compared with the control gas. A total of 28 control group infants and 30 iNO infants appeared well matched in terms of diagnoses, blood gases, oxygen indices and ventilator settings. </p> <p><a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a> was a single‐centre, open‐label trial in which treatment of participants included sedation and neuromuscular blockade. Infants in this trial were permitted to have previously received surfactant therapy or high‐frequency ventilation. Investigators initiated iNO therapy at 80 ppm after FiO<sub>2</sub> was reduced to 0.97, with a protocol that lowered the iNO dose to 40 ppm after one hour and with continued weaning if tolerated. Researchers discontinued iNO when a participant was cannulated for ECMO, or when the clinician chose to initiate high‐frequency ventilation. They evaluated the effectiveness of iNO by assessing alterations in oxygenation, mortality and use of ECMO. Investigators enrolled 51 participants, of whom they excluded two. Researchers randomised 23 included infants to receive conventional treatment and 26 to receive iNO. Only four participants in this study actually received surfactant treatment, and, as in previous studies, the most common diagnosis was meconium aspiration (in 45% of enrolled participants). This group has published follow‐up data, including neurodevelopmental outcomes that were obtained by telephone interview from 60 of 83 survivors of the original trial. They conducted the interview when participants were between one and four years of age. </p> <p><a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a> performed a multi‐centre study (funded by manufacturers) that compared three different doses of iNO (5 ppm, 20 ppm and 80 ppm) versus nitrogen placebo. Researchers hypothesised that iNO would reduce the incidence of a sequela included in the PPHN Major Sequelae Index (MSI), which they constructed. This index included death, ECMO, neurological sequelae and chronic lung disease. Investigators enrolled 155 infants with echocardiographic evidence of PPHN and PaO<sub>2</sub> between 40 and 100 mmHg in 100% oxygen, with a wide range of illness severity at enrolment. They excluded infants who received surfactant therapy and did not allow concurrent high‐frequency ventilation. They defined failure as PaO<sub>2</sub> less than 40 mmHg for longer than 30 minutes. This study was terminated early owing to poor enrolment. Researchers enrolled 155 infants; they entered 41 into the control group and 114 into one of the three iNO groups, with 41 receiving 5 ppm, 36 receiving 20 ppm and 37 receiving 80 ppm. </p> <p><a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a> was a randomised multi‐centre trial conducted at 33 French and Belgian neonatal units. Investigators enrolled 204 infants into the trial, 107 of whom were near‐term infants. Near‐term infants were entered at an OI between 15 and 40, which was confirmed on two blood gases taken one hour apart, and were treated with iNO at 10 ppm or with no iNO. Researchers excluded infants with pulmonary hypoplasia, including congenital diaphragmatic hernia. The primary outcome measure was OI at two hours. If an infant exceeded OI of 40 during the two‐hour period, iNO therapy was allowed. After the two‐hour assessment, further therapy was provided at the discretion of the physician, and it is not reported how many infants received iNO at this time. The randomisation procedure stratified infants according to gestation, mode of ventilation and pulmonary diagnosis. Two‐thirds of the infants had received surfactant, and just over half (57%) were given high‐frequency oscillatory ventilation. Thirty percent of the infants had meconium aspiration syndrome, 25% idiopathic PPHN and 45% RDS. Enrolment into the study was terminated because of slowing recruitment after 204 of the originally planned 360 infants had been entered. ECMO was not available as back‐up therapy; therefore, the number of infants dying was the same as the number of infants dying or requiring ECMO. </p> <p><a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a> randomised 42 infants of at least 34 weeks' gestation with respiratory failure and PaO<sub>2</sub> less than 100 mmHg on 100% oxygen, one of whom proved to have congenital heart disease and was removed from the study, leaving 41 study infants. Researchers compared iNO at 40 ppm versus standard therapy, without placebo gas. After one hour, they decreased the dose to 20 ppm if tolerated and made daily attempts at weaning iNO. The study was terminated early after an ad hoc committee reviewed the data. </p> <p><a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a> randomised 248 near‐term infants who were four days of age or younger with OI greater than 25, to 20 ppm of iNO or nitrogen placebo. Infants were not eligible if their PaO<sub>2</sub> was less than 30 mmHg and they were considered to be in urgent need of ECMO for refractory hypotension (mean blood pressure &lt; 35 mmHg). Investigators did not exclude infants with congenital diaphragmatic hernia, and these data are available as a separate stratum, allowing comparison of results with those of <a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a>. Researchers stratified infants by one of five diagnostic categories and then randomised them within that stratum. These strata included meconium aspiration, pneumonia, respiratory distress syndrome, lung hypoplasia syndromes including congenital diaphragmatic hernia and idiopathic persistent pulmonary hypertension. Echocardiographic or clinical confirmation of pulmonary hypertension was required. The primary outcome variable was the need for ECMO. After 24 hours of treatment with 20 ppm, investigators reduced the dose to 5 ppm for up to another 96 hours. Researchers evaluated secondary outcome variables of oxygen dependence at 30 days and neurological abnormality defined clinically or on ultrasonography. </p> <p><a href="./references#CD000399-bbs2-0008" title="FieldD , ElbourneD , HardyP , FentonAC , AhluwaliaJ , HallidayHL , et al. INNOVO Trial Collaborating Group. Neonatal ventilation with inhaled nitric oxide vs. ventilatory support without inhaled nitric oxide for infants with severe respiratory failure born at or near term: the INNOVO multicentre randomised controlled trial. Neonatology2007;91(2):73‐82. ">INNOVO 2007</a> randomised infants with more than 33 weeks' gestation if they had severe respiratory failure in the first 28 days of life, and 'if the responsible clinician was uncertain about whether an infant might benefit from iNO'. Researchers initiated iNO at 20 ppm or provided control intervention (without placebo gas). No cross‐over was allowed. Investigators enrolled 60 infants at European centres. Six of 31 controls received iNO; four iNO babies did not receive the gas, three improved and one died before the gas could be started. The primary outcome was death or severe disability at one year of age. Sample size was determined by a time limit for study duration. </p> <p><a href="./references#CD000399-bbs2-0011" title="LiuCQ , MaL , TangLM , HeXJ , WeiSF , WangSX , et al. A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2008;46(3):224‐8. ">Liu 2008</a>, which was conducted in China, limited participants to infants with meconium aspiration syndrome. Investigators required that infants have gestational age greater than 36 weeks and birth weight of at least 2.5 kg, and that intubated infants have an OI greater than 15. Infants did not receive surfactant; all underwent echocardiography during the initial workup but were not required to have pulmonary hypertension to be eligible. The primary outcome variable is not clear; iNO at 15 ppm or no additional gas was given, and iNO could be increased to 20 ppm in cases of poor response. </p> </section> <section id="CD000399-sec-0049"> <h5 class="title">Trials comparing iNO at moderate compared with severe criteria for illness severity</h5> <p><a href="./references#CD000399-bbs2-0001" title="BarefieldES , KarkeVA , PhillipsJB , CarloWA . Inhaled nitric oxide in term infants with hypoxemic respiratory failure. Journal of Pediatrics1996;129:279‐86. BarefieldES , KarkeVA , PhillipsJB , CarloWA . Randomized, controlled trial of inhaled NO in ECMO candidates. Pediatric Research1995;37:195A. ">Barefield 1996</a> compared iNO versus 'conventional treatment'. Infants had been treated with induction of alkalosis, both metabolic and respiratory, to obtain a pH of 7.65 or greater with partial pressure of carbon dioxide (PCO<sub>2</sub>) of 25 to 35 mmHg, and all infants were paralysed with vecuronium and sedated. Infants were not allowed to receive other vasodilators during the trial and were initially randomised to receive no iNO, iNO at a dose of 20 ppm for PaO<sub>2</sub> of 40 to 99 mmHg and iNO at 40 ppm for PaO<sub>2</sub> less than 40 mmHg; increases were allowed up to 80 ppm. Treatment failure occurred if PaO<sub>2</sub> was less than 80 mmHg for one hour "despite alkalosis", less than 40 mmHg for longer than one hour or less than 30 mmHg for 30 minutes. When control infants met treatment failure criteria, they were treated with iNO. The primary outcome of this trial was the need for ECMO or treatment failure. </p> <p><a href="./references#CD000399-bbs2-0006" title="DayRW , LynchJM . Acute hemodynamic and blood gas effects of inhaled nitric oxide in newborns with lung disease and pulmonary hypertension. Pediatric Research1996;39:330A. DayRW , LynchJM , WhiteKS , WardRM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics1996;98:698‐705. ">Day 1996</a> was a single‐centre study in which investigators randomised infants with OI between 25 and 40 to receive conventional therapy or 20 ppm of iNO, then treated control infants whose OI increased to greater than 40 with open‐label iNO. As a result, 22 infants treated in the randomised portion of the trial presented with OI between 25 and 40; 11 received iNO, and 11 conventional therapy. Much of this report combines infants randomised to iNO and some non‐randomised infants who received iNO as well as control infants who crossed over to iNO. We have included data only when they were clearly derived from the initially randomised comparison. </p> <p><a href="./references#CD000399-bbs2-0016" title="SadiqFH , Illinois Multicenter Trial. Treatment of persistent pulmonary hypertension of the newborn with nitric oxide: a randomized trial. Pediatric Research1998;43:192A. SadiqHF , MantychG , BenawraRS , DevaskarUP , HockerJR . Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. Journal of Perinatology2003;23:98‐103. ">Sadiq 1998</a> randomised infants with birth weight &gt; 2 kg on assisted ventilation with 100% oxygen and an A‐aDO<sub>2</sub> between 500 and 599 mmHg on two blood gases at least one hour apart to iNO (10 to 80 ppm) or standard medical management. Echocardiographic evidence of pulmonary hypertension was required, and infants must have received at least one dose of surfactant before enrolment. The primary outcome criterion was "severe pulmonary hypertension", which was defined as A‐aDO<sub>2</sub> greater than 600 mmHg. If infants satisfied this definition, then iNO and other therapies including ECMO were allowed. Infants with congenital diaphragmatic hernia were enrolled, and only those with "lethal anomalies" were excluded. </p> <p><a href="./references#CD000399-bbs2-0004" title="CornfieldDN , MaynardRC , deRegnierRA , GuiangSF3rd , BarbatoJE , MillaCE . Randomized, controlled trial of low‐dose inhaled nitric oxide in the treatment of term and near‐term infants with respiratory failure and pulmonary hypertension. Pediatrics1999;104:1089‐94. ">Cornfield 1999</a> was a randomised study conducted at three centres that compared 2 ppm of iNO versus control. The hypothesis of this study was that low‐dose iNO would acutely improve oxygenation. The study was unblinded. Investigators enrolled 38 full‐term infants with OI over 25, nine of whom had a congenital diaphragmatic hernia. After the initial one‐hour period, if infants in either group had OI greater than 35, they were considered treatment failures and received 20 ppm of iNO. Thus the trial could be considered a trial of moderate (OI &gt; 25) compared with severe (OI &gt; 35) criteria for iNO, even though investigators used different concentrations for those criteria. </p> <p><a href="./references#CD000399-bbs2-0010" title="KonduriGG , SolimanoA , SokolGM , SingerJ , EhrenkranzRA , SinghalN , et al. Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near‐term newborn infants with hypoxic respiratory failure. Pediatrics2004;113(3 Pt 1):559‐64. KonduriGG , VohrB , RobertsonC , SokolGM , SolimanoA , SingerJ , et al. Early inhaled nitric oxide therapy for term and near‐term newborn infants with hypoxic respiratory failure: neurodevelopmental follow‐up. Journal of Pediatrics2007;150(3):235‐40.e1. ">Konduri 2004</a> randomised infants at ≥ 34 weeks' gestation on assisted ventilation with OI between 15 and 25 and with FiO<sub>2</sub> of 0.80 on any two arterial blood gases, at least 15 minutes and not more than 12 hours apart, to iNO at 5 to 20 ppm or placebo (nitrogen gas). Investigators started iNO at 5 ppm and increased the dose to a maximum of 20 ppm when they noted a partial response (adjustments were made by a single unmasked therapist, and the remainder of the team were masked). Researchers excluded infants with congenital diaphragmatic hernia or cardiac malformation and those older than 14 days. The primary outcome was death or the need for ECMO. The control group received iNO if OI exceeded 25. </p> <p><a href="./references#CD000399-bbs2-0007" title="GonzalezA , FabresJ , D'ApremontI , UrcelayG , AvacaM , GandolfiC , et al. Randomized controlled trial of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension. Journal of Perinatology2010;30(6):420‐4. ">Gonzalez 2010</a>, a two‐centre study conducted in Chile, randomised near‐term and term infants with OI between 10 and 30 to receive iNO at 20 ppm or control; if within 48 hours, OI worsened to 40 or more, then controls received iNO. Infants who remained with OI greater than 40 were treated with high‐frequency ventilation. All infants had echocardiographic evidence of PPHN, but investigators did not state whether they received surfactant. The primary outcome variable was progression to OI over 40. </p> </section> <section id="CD000399-sec-0050"> <h5 class="title">Trials comparing iNO versus high‐frequency ventilation</h5> <p><a href="./references#CD000399-bbs2-0009" title="KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariE , ClarkRH , et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency ventilation in severe persistent pulmonary hypertension of the newborn. Pediatric Research1996;39:222A. KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariEE , MayockDE , et al. Randomized, multicenter trial of inhaled nitric oxide and high‐frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. Journal of Pediatrics1997;131:55‐62. ">Kinsella 1997</a> compared iNO versus high‐frequency ventilation rather than against 'standard therapy'; if infants failed the first therapy, they were crossed over to the alternate therapy, then to combined treatment. Data from this study included in this review relate only to the first comparison between initially randomised groups. This multi‐centre study excluded infants with lethal abnormalities and proscribed the use of surfactant after enrolment. The definition of success in this trial was achievement of a PaO<sub>2</sub> greater than 60 mmHg with assigned therapy. Initial randomisation was to iNO 20 to 40 ppm or to high‐frequency ventilation with the SensorMedics oscillator (SensorMedics Corporation, Yorba Linda, California, USA). The trial had enrolled 205 infants when it was terminated as the result of an interim analysis that demonstrated lack of efficacy. Thirty‐one percent of the infants included in this trial had received surfactant before enrolment. As this is the only trial included in this group, we did not perform a meta‐analysis, and all infants had the possibility of receiving iNO at some point in the trial. Therefore, we included data on short‐term oxygenation changes after iNO but did not analyse clinical outcome data. </p> <p>All of the studies described above, with the exception of <a href="./references#CD000399-bbs2-0009" title="KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariE , ClarkRH , et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency ventilation in severe persistent pulmonary hypertension of the newborn. Pediatric Research1996;39:222A. KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariEE , MayockDE , et al. Randomized, multicenter trial of inhaled nitric oxide and high‐frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. Journal of Pediatrics1997;131:55‐62. ">Kinsella 1997</a>, <a href="./references#CD000399-bbs2-0006" title="DayRW , LynchJM . Acute hemodynamic and blood gas effects of inhaled nitric oxide in newborns with lung disease and pulmonary hypertension. Pediatric Research1996;39:330A. DayRW , LynchJM , WhiteKS , WardRM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics1996;98:698‐705. ">Day 1996</a> and <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a>, excluded infants with congenital diaphragmatic hernia (CDH). This patient population is unique in presentation and pathophysiology. As a result, NINOS investigators performed a parallel study of infants with CDH using an identical study protocol to the main NINOS study (<a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a>). They enrolled 53 infants (28 control, 25 iNO treated), and their primary hypothesis was that iNO would reduce the occurrence of death or the need for ECMO at 120 days. Treated and control groups were well matched, with baseline OI of 45.8 ± 16.3 in controls and 44.5 ± 14.5 in iNO‐treated infants. </p> </section> </section> <section id="CD000399-sec-0051"> <h4 class="title">Excluded studies</h4> <p>See the <a href="./references#CD000399-sec-0100" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD000399-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>The overall quality of these studies is highly variable. The highest‐quality studies were fully blinded, adequately powered, multi‐centre RCTs with external data monitoring groups that examined clinically important outcomes (<a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996;</a><a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997;</a><a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a>; <a href="./references#CD000399-bbs2-0010" title="KonduriGG , SolimanoA , SokolGM , SingerJ , EhrenkranzRA , SinghalN , et al. Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near‐term newborn infants with hypoxic respiratory failure. Pediatrics2004;113(3 Pt 1):559‐64. KonduriGG , VohrB , RobertsonC , SokolGM , SolimanoA , SingerJ , et al. Early inhaled nitric oxide therapy for term and near‐term newborn infants with hypoxic respiratory failure: neurodevelopmental follow‐up. Journal of Pediatrics2007;150(3):235‐40.e1. ">Konduri 2004</a>). Another group of studies of intermediate quality used variable degrees of blinding or examined primarily oxygenation outcomes (<a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>; <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>; <a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998;</a><a href="./references#CD000399-bbs2-0016" title="SadiqFH , Illinois Multicenter Trial. Treatment of persistent pulmonary hypertension of the newborn with nitric oxide: a randomized trial. Pediatric Research1998;43:192A. SadiqHF , MantychG , BenawraRS , DevaskarUP , HockerJR . Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. Journal of Perinatology2003;23:98‐103. ">Sadiq 1998</a>; <a href="./references#CD000399-bbs2-0008" title="FieldD , ElbourneD , HardyP , FentonAC , AhluwaliaJ , HallidayHL , et al. INNOVO Trial Collaborating Group. Neonatal ventilation with inhaled nitric oxide vs. ventilatory support without inhaled nitric oxide for infants with severe respiratory failure born at or near term: the INNOVO multicentre randomised controlled trial. Neonatology2007;91(2):73‐82. ">INNOVO 2007</a>). A third group of studies consisted of single (or few)‐centre studies that were unblinded and included very small sample sizes (<a href="./references#CD000399-bbs2-0001" title="BarefieldES , KarkeVA , PhillipsJB , CarloWA . Inhaled nitric oxide in term infants with hypoxemic respiratory failure. Journal of Pediatrics1996;129:279‐86. BarefieldES , KarkeVA , PhillipsJB , CarloWA . Randomized, controlled trial of inhaled NO in ECMO candidates. Pediatric Research1995;37:195A. ">Barefield 1996</a>; <a href="./references#CD000399-bbs2-0006" title="DayRW , LynchJM . Acute hemodynamic and blood gas effects of inhaled nitric oxide in newborns with lung disease and pulmonary hypertension. Pediatric Research1996;39:330A. DayRW , LynchJM , WhiteKS , WardRM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics1996;98:698‐705. ">Day 1996</a>; <a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996;</a><a href="./references#CD000399-bbs2-0004" title="CornfieldDN , MaynardRC , deRegnierRA , GuiangSF3rd , BarbatoJE , MillaCE . Randomized, controlled trial of low‐dose inhaled nitric oxide in the treatment of term and near‐term infants with respiratory failure and pulmonary hypertension. Pediatrics1999;104:1089‐94. ">Cornfield 1999</a>; <a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a>; <a href="./references#CD000399-bbs2-0011" title="LiuCQ , MaL , TangLM , HeXJ , WeiSF , WangSX , et al. A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2008;46(3):224‐8. ">Liu 2008;</a><a href="./references#CD000399-bbs2-0007" title="GonzalezA , FabresJ , D'ApremontI , UrcelayG , AvacaM , GandolfiC , et al. Randomized controlled trial of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension. Journal of Perinatology2010;30(6):420‐4. ">Gonzalez 2010</a>). </p> <p><a href="./references#CD000399-bbs2-0009" title="KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariE , ClarkRH , et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency ventilation in severe persistent pulmonary hypertension of the newborn. Pediatric Research1996;39:222A. KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariEE , MayockDE , et al. Randomized, multicenter trial of inhaled nitric oxide and high‐frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. Journal of Pediatrics1997;131:55‐62. ">Kinsella 1997</a> is a unique study of high quality that had a rather complex protocol and cannot be directly compared with the remaining studies, as investigators compared iNO versus high‐frequency ventilation. Several studies were terminated early. In the case of <a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>, this occurred because predetermined stopping rules were satisfied. In other cases (<a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>; <a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a>; <a href="./references#CD000399-bbs2-0016" title="SadiqFH , Illinois Multicenter Trial. Treatment of persistent pulmonary hypertension of the newborn with nitric oxide: a randomized trial. Pediatric Research1998;43:192A. SadiqHF , MantychG , BenawraRS , DevaskarUP , HockerJR . Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. Journal of Perinatology2003;23:98‐103. ">Sadiq 1998</a>; <a href="./references#CD000399-bbs2-0010" title="KonduriGG , SolimanoA , SokolGM , SingerJ , EhrenkranzRA , SinghalN , et al. Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near‐term newborn infants with hypoxic respiratory failure. Pediatrics2004;113(3 Pt 1):559‐64. KonduriGG , VohrB , RobertsonC , SokolGM , SolimanoA , SingerJ , et al. Early inhaled nitric oxide therapy for term and near‐term newborn infants with hypoxic respiratory failure: neurodevelopmental follow‐up. Journal of Pediatrics2007;150(3):235‐40.e1. ">Konduri 2004</a>), it occurred because of slowing enrolment; in <a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a>, it followed examination of data. </p> <p>Risk of bias summaries are shown in <a href="#CD000399-fig-0002">Figure 2</a> and <a href="#CD000399-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD000399-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000399-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD000399-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000399-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD000399-sec-0053"> <h4 class="title">Studies at low risk of bias</h4> <p><a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>: In this masked multi‐centre trial, investigators masked allocation, intervention and outcome assessment. Investigators performed preplanned interim analyses and used standard stopping rules. They noted the significance of the primary outcome variable after performing the second analysis. </p> <p><a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a>: This trial was designed in an unusual and pragmatic fashion to run simultaneously at the same centres as the main study (<a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>), with a sample size that was planned by terminating enrolment when the main Ninos study was complete. Investigators performed allocation, intervention and outcome analysis in a masked fashion. Investigators reported long‐term neurodevelopmental follow‐up of infants in <a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996,</a> and in <a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a>, they reported survival of 87% for <a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a> (n = 173) and 76% for <a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a> (n = 53). All but seven assessments were blinded to original treatment. Non‐blinded BSID administrators assessed control infants and six iNO‐treated infants. </p> <p><a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a>: This multi‐centre trial reported masked allocation and intervention and complete follow‐up. The published manuscript does not mention a prespecified sample size. </p> <p><a href="./references#CD000399-bbs2-0010" title="KonduriGG , SolimanoA , SokolGM , SingerJ , EhrenkranzRA , SinghalN , et al. Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near‐term newborn infants with hypoxic respiratory failure. Pediatrics2004;113(3 Pt 1):559‐64. KonduriGG , VohrB , RobertsonC , SokolGM , SolimanoA , SingerJ , et al. Early inhaled nitric oxide therapy for term and near‐term newborn infants with hypoxic respiratory failure: neurodevelopmental follow‐up. Journal of Pediatrics2007;150(3):235‐40.e1. ">Konduri 2004</a>: This multi‐centre study used central randomisation allocation and masking of the intervention. Researchers compared thresholds of OI 15 to 25 versus OI &gt; 25. Unfortunately, slow enrolment led to early termination of the study and a reduction in power. This was done without review of results and should not affect the validity of study conclusions. </p> </section> <section id="CD000399-sec-0054"> <h4 class="title">Studies at intermediate risk of bias</h4> <p><a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>: Sample size determination leaves this study open to the criticism of little protection against type 1 error, in that study authors reported that they planned to stop after enrolling 50 participants if results showed significant improvement in oxygenation. Review authors made no adjustments to the critical P value for multiple looks at the data. Researchers did not report the study hypothesis. </p> <p><a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>: A three‐to‐one randomisation scheme enabled the provision of dose‐response oxygenation information but limited the number of controls. This study was terminated early and was therefore underpowered to detect clinical benefit. </p> <p><a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a>: This multi‐centre trial reported masked allocation and complete follow‐up but no masking of the intervention. Many protocol violations were noted (44 of the 54 assigned to control therapy received iNO, and only 55 of the 62 assigned to iNO received this treatment). </p> <p><a href="./references#CD000399-bbs2-0016" title="SadiqFH , Illinois Multicenter Trial. Treatment of persistent pulmonary hypertension of the newborn with nitric oxide: a randomized trial. Pediatric Research1998;43:192A. SadiqHF , MantychG , BenawraRS , DevaskarUP , HockerJR . Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. Journal of Perinatology2003;23:98‐103. ">Sadiq 1998</a>: This multi‐centre study included a relatively small sample and was terminated owing to slowing enrolment. The intervention was not masked. Review authors requested data on death and ECMO, and the principal investigator provided them. </p> <p><a href="./references#CD000399-bbs2-0008" title="FieldD , ElbourneD , HardyP , FentonAC , AhluwaliaJ , HallidayHL , et al. INNOVO Trial Collaborating Group. Neonatal ventilation with inhaled nitric oxide vs. ventilatory support without inhaled nitric oxide for infants with severe respiratory failure born at or near term: the INNOVO multicentre randomised controlled trial. Neonatology2007;91(2):73‐82. ">INNOVO 2007</a>: The term section of the INNOVO study enrolled only 60 participants from 27 participating hospitals over four years (15 hospitals actually contributed patients). Recruitment ended when the preterm portion of the trial ended. The entry criteria made it difficult to extrapolate study results to other populations, but infants were very sick with 25% mortality, and almost half had OI over 40 at enrolment. </p> <p><a href="./references#CD000399-bbs2-0007" title="GonzalezA , FabresJ , D'ApremontI , UrcelayG , AvacaM , GandolfiC , et al. Randomized controlled trial of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension. Journal of Perinatology2010;30(6):420‐4. ">Gonzalez 2010</a>: This two‐centre trial randomised near‐term infants with OI between 10 and 30 to iNO at 20 ppm or to no iNO. All infants whose condition deteriorated to reach OI of 40 received iNO and could receive high‐frequency ventilation; if already receiving iNO, investigators added high‐frequency ventilation. ECMO in case of failure was not available. Randomisation was described only as sequenced sealed envelopes and may have been masked, but this is not certain. Investigators calculated the sample size on the basis of a very large predicted effect and achieved this goal. They did not mask the intervention. </p> </section> <section id="CD000399-sec-0055"> <h4 class="title">Studies at higher risk of bias</h4> <p><a href="./references#CD000399-bbs2-0001" title="BarefieldES , KarkeVA , PhillipsJB , CarloWA . Inhaled nitric oxide in term infants with hypoxemic respiratory failure. Journal of Pediatrics1996;129:279‐86. BarefieldES , KarkeVA , PhillipsJB , CarloWA . Randomized, controlled trial of inhaled NO in ECMO candidates. Pediatric Research1995;37:195A. ">Barefield 1996:</a> This very small study included somewhat unbalanced groups at enrolment; the mean OI at entry was 26 in the control group and 38 in the treatment group. Infants receiving iNO also appeared to have a lower pH (7.46 ± 0.06 vs 7.61 ± 0.07), higher partial pressure of arterial carbon dioxide (PaCO<sub>2</sub>) (40 ± 7 vs 28 ± 4 mmHg) and lower PaO<sub>2</sub> (49 ± 7 vs 63 ± 7 mmHg). Study authors did not clearly describe the study hypothesis. The sample size calculation required 24 participants per group, but the basis for this calculated sample size is not clear. Study authors did not explain why the study was discontinued before the calculated sample size was enrolled. </p> <p><a href="./references#CD000399-bbs2-0006" title="DayRW , LynchJM . Acute hemodynamic and blood gas effects of inhaled nitric oxide in newborns with lung disease and pulmonary hypertension. Pediatric Research1996;39:330A. DayRW , LynchJM , WhiteKS , WardRM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics1996;98:698‐705. ">Day 1996</a>: Study authors did not state how the sample size was calculated and reported no study hypothesis. The method of randomisation is unclear and was described as a 'blind draw'. Researchers reported the study objective as to "review the acute effects" of iNO. </p> <p><a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a>: This small single‐centre study provided unmasked intervention and did not adequately describe allocation; review authors could not ascertain whether it was masked. </p> <p><a href="./references#CD000399-bbs2-0004" title="CornfieldDN , MaynardRC , deRegnierRA , GuiangSF3rd , BarbatoJE , MillaCE . Randomized, controlled trial of low‐dose inhaled nitric oxide in the treatment of term and near‐term infants with respiratory failure and pulmonary hypertension. Pediatrics1999;104:1089‐94. ">Cornfield 1999</a>: Study authors did not clearly describe the randomisation procedure, and masking of allocation is unclear. Study authors planned to enrol 60 participants. They planned an interim analysis at two‐thirds of full enrolment to be performed blind. The study was terminated after this interim analysis (n = 38) because a secondary analysis (i.e. response to 20 ppm after failure of initial therapy) differed between groups. Early termination of this trial was the result of an unexpected finding with limited clinical significance, and no difference in clinically important outcomes seriously limited the power of this study. </p> <p><a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a>: This study included a limited sample size, as the study was terminated after <a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a> and <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a> reported results. Study authors did not explicitly state the hypothesis, and they listed study objectives as determining whether iNO improves oxygenation in infants given high‐frequency ventilation; however, not all infants received this mode of ventilation. </p> <p><a href="./references#CD000399-bbs2-0011" title="LiuCQ , MaL , TangLM , HeXJ , WeiSF , WangSX , et al. A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2008;46(3):224‐8. ">Liu 2008</a>: This single‐centre trial noted no prespecified sample size and is the only trial that restricted enrolment to infants with meconium aspiration syndrome; ECMO was not available as rescue therapy. The intervention was unmasked, and researchers provided little detail about the mechanics of randomisation. </p> </section> </section> <section id="CD000399-sec-0056"> <h3 class="title" id="CD000399-sec-0056">Effects of interventions</h3> <p>See: <a href="./full#CD000399-tbl-0001"><b>Summary of findings for the main comparison</b> Inhaled NO compared with control for respiratory failure in infants born at or near term</a>; <a href="./full#CD000399-tbl-0002"><b>Summary of findings 2</b> Inhaled NO at moderate compared with severe criteria for illness severity in respiratory failure among infants born at or near term</a> </p> <section id="CD000399-sec-0057"> <h4 class="title">Comparison 1: iNO versus control (no iNO) in infants with hypoxic respiratory failure</h4> <section id="CD000399-sec-0058"> <h5 class="title">Outcome 1.1: Death or use of ECMO</h5> <p>This outcome was reported by 10 trials (<a href="./references#CD000399-fig-0004" title="">Analysis 1.1</a>). Nine studies (<a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>; <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>; <a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a>; <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>; <a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a>; <a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a>; <a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a>; <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a>; <a href="./references#CD000399-bbs2-0008" title="FieldD , ElbourneD , HardyP , FentonAC , AhluwaliaJ , HallidayHL , et al. INNOVO Trial Collaborating Group. Neonatal ventilation with inhaled nitric oxide vs. ventilatory support without inhaled nitric oxide for infants with severe respiratory failure born at or near term: the INNOVO multicentre randomised controlled trial. Neonatology2007;91(2):73‐82. ">INNOVO 2007</a>; <a href="./references#CD000399-bbs2-0011" title="LiuCQ , MaL , TangLM , HeXJ , WeiSF , WangSX , et al. A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2008;46(3):224‐8. ">Liu 2008</a>) did not allow use of iNO in controls who did not respond. One of these trials (<a href="./references#CD000399-bbs2-0011" title="LiuCQ , MaL , TangLM , HeXJ , WeiSF , WangSX , et al. A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2008;46(3):224‐8. ">Liu 2008</a>) did not have ECMO available; therefore, the frequency of death reported is equal to death or requirement for ECMO. One study gave the randomised intervention for only two hours before allowing iNO among controls (<a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a>). </p> <p>One study (<a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997)</a> included infants with CDH and reported the CDH stratum of <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a> as a separate subgroup. Investigators reported all outcomes of this subgroup separately (see below). </p> <p>Four studies (<a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>; <a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a>; <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a> and the non‐CDH stratum of <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>) found a statistically significant reduction in the combined outcome of death or requirement for ECMO. Meta‐analysis of the eight trials in the subgroup without back‐up iNO treatment and without participants with CDH revealed that iNO treatment resulted in a reduction in the incidence of death or requirement for ECMO (typical RR 0.66, 95% CI 0.57 to 0.77; eight studies, 859 infants; typical RD ‐0.18, 95% CI ‐0.25 to ‐0.12) (high‐quality evidence) and showed little heterogeneity (I<sup>2</sup> = 21%). Sensitivity analysis revealed that exclusion of studies at higher risk of bias (<a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a>; <a href="./references#CD000399-bbs2-0011" title="LiuCQ , MaL , TangLM , HeXJ , WeiSF , WangSX , et al. A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2008;46(3):224‐8. ">Liu 2008</a>) had no effect on the risk ratio of this outcome but reduced heterogeneity (I<sup>2</sup>) to zero. </p> <p>The study that allowed back‐up iNO among controls (<a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a>) did not report a significant effect for this outcome. </p> </section> <section id="CD000399-sec-0059"> <h5 class="title">Outcome 1.2: Death before hospital discharge</h5> <p>The same studies also reported death (<a href="./references#CD000399-fig-0005" title="">Analysis 1.2</a>). None of the individual studies found a significant effect. Likewise, meta‐analysis revealed no evidence of effect (typical RR 0.89, 95% CI 0.60 to 1.31; eight studies, 860 infants; typical RD ‐0.01, 95% CI ‐0.05 to 0.03) (high‐quality evidence). On sensitivity analysis, after trials at high risk of bias were excluded, the RR was 0.93 and confidence intervals were wide. </p> </section> <section id="CD000399-sec-0060"> <h5 class="title">Outcome 1.3: Use of ECMO before hospital discharge</h5> <p>Seven studies reported this outcome (<a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>; <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>; <a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a>; <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>; <a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a>; <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a>; <a href="./references#CD000399-bbs2-0008" title="FieldD , ElbourneD , HardyP , FentonAC , AhluwaliaJ , HallidayHL , et al. INNOVO Trial Collaborating Group. Neonatal ventilation with inhaled nitric oxide vs. ventilatory support without inhaled nitric oxide for infants with severe respiratory failure born at or near term: the INNOVO multicentre randomised controlled trial. Neonatology2007;91(2):73‐82. ">INNOVO 2007</a>). Meta‐analysis of results of these studies in this subgroup supported a significant effect (typical RR 0.60, 95% CI 0.50 to 0.71; seven studies, 815 infants; typical RD ‐0.20, 95% CI ‐0.27 to ‐0.14) (<a href="./references#CD000399-fig-0006" title="">Analysis 1.3</a>). Thus, the number needed to treat with iNO for an additional beneficial outcome (NNTB) to prevent one infant from requiring ECMO was 5 (95% CI 3.7 to 7.1) (high‐quality evidence). On sensitivity analysis, exclusion of <a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a> had no effect (<a href="./references#CD000399-bbs2-0011" title="LiuCQ , MaL , TangLM , HeXJ , WeiSF , WangSX , et al. A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2008;46(3):224‐8. ">Liu 2008</a> did not have ECMO available). </p> </section> <section id="CD000399-sec-0061"> <h5 class="title">Outcome 1.4: Failure to improve oxygenation (PaO<sub>2</sub>) </h5> <p>Two studies in this group reported this outcome (<a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>; <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>). Both trials reported a statistically significant benefit of iNO, with fewer infants failing to have improved oxygenation (<a href="./references#CD000399-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD000399-sec-0062"> <h5 class="title">Outcome 1.5: OI 30 to 60 minutes after the start of treatment</h5> <p>Five studies reported this outcome (<a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>; <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>; <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>; <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a>; <a href="./references#CD000399-bbs2-0011" title="LiuCQ , MaL , TangLM , HeXJ , WeiSF , WangSX , et al. A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2008;46(3):224‐8. ">Liu 2008</a>) (<a href="./references#CD000399-fig-0008" title="">Analysis 1.5</a>) and found a statistically significant benefit of iNO. The results are remarkably homogeneous across studies. Meta‐analysis shows that OI 30 to 60 minutes after therapy commenced was significantly lower in the iNO group (weighted mean difference ‐8.45, 95% CI ‐11.42 to ‐5.48; five studies, 709 infants). <a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a> reported median changes in OI after 60 minutes of ‐18 in the iNO group and 0 in the control group. <a href="./references#CD000399-bbs2-0012" title="Franco‐Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet1999;354:1066‐71. MercierJC , DehanM , BreartG , ClementS , O'NodyP . Inhaled nitric oxide in neonatal respiratory failure. Pediatric Research1998;43:290A. ">Mercier 1998</a> reported OI results at two hours after the start of treatment as median and interquartile ranges. Therefore, we cannot currently add these data to our analysis. However, the direction and magnitude of the effect of iNO were very similar: Among controls, median OI at baseline was 21.7 with little change at two hours (median 19.4), whereas in those given iNO, median OI at baseline was 25.9 and fell to 15.8 at two hours. The two‐hour OI was significantly different between groups, as was the absolute change in OI (median ‐2.7 in the control group vs ‐7.8 in the iNO group). </p> </section> <section id="CD000399-sec-0063"> <h5 class="title">Outcome 1.6: PaO<sub>2</sub> 30 to 60 minutes after treatment </h5> <p>Four studies reported this outcome (<a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>; <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a>; <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>; <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a>) (<a href="./references#CD000399-fig-0009" title="">Analysis 1.6</a>). All found statistically significant benefit of iNO. Study results are remarkably homogeneous. Meta‐analysis shows that PaO<sub>2</sub> 30 to 60 minutes after treatment was statistically significantly higher in the iNO group (weighted mean difference 32.62 mmHg, 95% CI 23.56 to 41.67; five studies, 707 infants). <a href="./references#CD000399-bbs2-0002" title="ChristouH , VanMarterLJ , WesselDL , AllredEN , KaneJW , ThompsonJE , et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Critical Care Medicine2000;28:3722‐7. ">Christou 2000</a> reported median changes in PaO<sub>2</sub> of 53 mmHg in the iNO group and 2 mmHg in the control group. </p> </section> <section id="CD000399-sec-0064"> <h5 class="title">Outcomes 1.7: Change in OI after treatment; and 1.8: Change in PaO<sub>2</sub> after treatment </h5> <p>Only the Ninos trials reported these outcomes; both showed substantial improvement in PaO<sub>2</sub> and decreased OI (<a href="./references#CD000399-fig-0010" title="">Analysis 1.7</a>; <a href="./references#CD000399-fig-0011" title="">Analysis 1.8</a>). For both outcomes, the change was statistically significant only among infants in the main trial who did not have congenital diaphragmatic hernia. </p> </section> <section id="CD000399-sec-0065"> <h5 class="title">Outcomes 1.9 to 1.13: Neurodevelopmental and other late outcomes</h5> <p>Four studies reported these outcomes (<a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>; <a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a>; <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>; <a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a>) (<a href="./references#CD000399-fig-0012" title="">Analysis 1.9</a>; <a href="./references#CD000399-fig-0013" title="">Analysis 1.10</a>; <a href="./references#CD000399-fig-0014" title="">Analysis 1.11</a>; <a href="./references#CD000399-fig-0015" title="">Analysis 1.12</a>; <a href="./references#CD000399-fig-0016" title="">Analysis 1.13</a>). The <a href="./references#CD000399-bbs2-0043" title="Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the neonatal inhaled nitric oxide study group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 2000</a> publication reported neurodevelopmental outcomes from both <a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a> and <a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a>, and <a href="./references#CD000399-bbs2-0041" title="LipkinPH , DavidsonD , SpivakL , StraubeR , RhinesJ , ChangCT . Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. Journal of Pediatrics2002;140:306‐10. ">Lipkin 2002</a> reported outcomes of <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>. <a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a> reported neurodevelopmental outcomes obtained by telephone interview. </p> <p>For survivors of <a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996</a>, investigators performed BSID II testing (n = 154), a neurological examination (n = 172) and hearing tests (n = 157). Results showed no significant differences in the occurrence of neurodevelopmental sequelae between iNO and control infants: 18/87 control infants and 19/85 iNO infants did not have normal neurological examination findings, and 9/87 controls compared with 10/85 iNO infants had cerebral palsy (CP). Investigators observed no differences in the occurrence of hearing impairment (defined as a threshold &gt; 40 db; 23/82 evaluated controls vs 24/75 evaluated iNO infants) nor in scores on the BSID (Mental Development Index (MDI) 87 ± 18.7 for control infants vs 85 ± 21.7 for iNO infants; Physical Development Index (PDI) 93.6 ± 17.5 for control infants vs 85.7 ± 21.2 for iNO infants). One or more neurodevelopmental disabilities occurred in 26/87 control infants compared with 29/85 iNO infants. The occurrence of seizures was less among iNO infants (13/87 control infants vs 4/85 iNO infants; P = 0.046). In addition, investigators reported no differences in requirements for later hospital readmission, use of home medications, apnoea monitors, home oxygen, use of gastrostomy tubes or requirement for speech therapy. Researchers did not report outcomes of all infant testing conducted in <a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a> and stated that they found no differences in the mean results of BSID examinations, and proportions with scores lower than 70 were similar. </p> <p>Investigators from <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a> examined 35 control infants and 94 iNO‐treated infants at an average of 13 months of age by performing a neurological examination ‐ Bayley Scales of Infant Development (BSID) ‐ and audiological assessment. The prevalence of CP, developmental delay (BSID scores &gt; 2 SD below the mean) and hearing impairment (defined as mild 25 to 50 db threshold, or severe &gt; 50 db) was not different between groups. The general health of infants in terms of hospitalisation and growth was not different between groups. </p> <p><a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a> used different scales and relied on a telephone interview to record outcome data. Researchers observed no differences in the developmental quotient calculated from the Motor and Social Development Scale of the 1981 Child Health Supplement to the National Health Interview Survey. The reliability, reproducibility and validity of this scale have received little attention. The number of infants with a quotient less than 70 was greater among the control group (4/25) than among the iNO group (0/35). Although cerebral palsy, visual disability and hearing and speech disabilities were reported, it is unclear how these terms were defined, and the incidence of overall neurological disability included seizures. Therefore, it is not possible for review authors to add any of these data to the meta‐analysis, but they do appear to show no evidence of neurodevelopmental impairment due to iNO therapy. The study included an assessment of general and pulmonary health; 31% of iNO participants (n = 35) and 20% of control participants (n = 20) had required hospital readmission, and 14% of iNO participants and 24% of control participants were found to have reactive airways disease; neither of these events was statistically significant. </p> <p>Definitions used by the Ninos group and by Lipkin and coworkers for the overall incidence of neurodevelopmental disability were dissimilar. The Ninos group reported the incidence of having one or more disabilities (CP, BSID MDI or PDI &lt; 2 SD, blindness or hearing impairment). <a href="./references#CD000399-bbs2-0041" title="LipkinPH , DavidsonD , SpivakL , StraubeR , RhinesJ , ChangCT . Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. Journal of Pediatrics2002;140:306‐10. ">Lipkin 2002</a> reported the incidence of mild (one or two mild impairments, including mild neurological abnormalities and mild reduction in scores on the BSID ‐ between 1 and 2 SDs below the mean) and severe impairments (CP, more than two mild impairments, or at least one severe impairment). If we proceed on the assumption that the definition of severe impairment in <a href="./references#CD000399-bbs2-0041" title="LipkinPH , DavidsonD , SpivakL , StraubeR , RhinesJ , ChangCT . Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. Journal of Pediatrics2002;140:306‐10. ">Lipkin 2002</a> is similar enough to the Ninos definition of one or more neurodevelopmental disabilities for a combined analysis, we find no effect of iNO (typical RR of adverse outcomes 0.97, 95% CI 0.66 to 1.44) (low‐quality evidence). </p> </section> </section> <section id="CD000399-sec-0066"> <h4 class="title">Comparison 1, subgroup analysis: iNO versus control (no iNO) in infants with hypoxic respiratory failure (subgroup of infants with CDH) </h4> <p>Infants with CDH do not appear to share the benefits of iNO; indeed it has been suggested that outcomes could be worse in infants with CDH who receive iNO compared with control infants. We have combined the results of <a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a> with the diaphragmatic hernia stratum of <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a> ‐ the only other study from which such information can be extrapolated. </p> <section id="CD000399-sec-0067"> <h5 class="title">Outcome 1.1.3: Death or requirement for ECMO in infants with CDH</h5> <p>The incidence of death or requirement for ECMO was 40/46 control infants and 36/38 infants with iNO (RR 1.09, 95% CI 0.95 to 1.26; two studies, 84 infants; RD 0.08, 95% CI ‐0.04 to 0.20) (<a href="./references#CD000399-fig-0004" title="">Analysis 1.1</a>.3). </p> </section> <section id="CD000399-sec-0068"> <h5 class="title">Outcome 1.2.3: Death in infants with CDH</h5> <p>Mortality rate was not changed: 18/46 control infants compared with 18/38 infants with iNO (RR 1.20, 95% CI 0.74 to 1.96; two studies, 84 infants; RD 0.08, 95% CI ‐0.13 to 0.29) (<a href="./references#CD000399-fig-0005" title="">Analysis 1.2</a>.3). </p> </section> <section id="CD000399-sec-0069"> <h5 class="title">Outcome 1.3.2: Requirement for ECMO in infants with CDH</h5> <p>Results showed a barely significant increase in the requirement for ECMO: 31/46 control infants compared with 32/38 infants with iNO (RR 1.27, 95% CI 1.00 to 1.62; two studies, 84 infants; RD 0.18, 95% CI 0.01 to 0.35) (<a href="./references#CD000399-fig-0006" title="">Analysis 1.3</a>.2). This occurred despite the fact that infants with CDH who received iNO were more likely to improve their oxygenation (data from <a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a> only; all control infants failed to improve oxygenation compared with 20/24 iNO infants; RR of failure to improve oxygenation 0.83, 95% CI, 0.70 to 1.00). The mean difference in PaO<sub>2</sub>, however, was small and was not statistically significant. PaO<sub>2</sub> 30 minutes after treatment increased by 7.8 mmHg in iNO infants compared with 1.1 mmHg in control infants (MD 6.7, 95% CI 15.7 to ‐2.3), and OI decreased by 2.7 in iNO infants compared with an increase of 4.0 among control infants (MD ‐6.70, 95% CI ‐18.39 to +4.99). </p> </section> <section id="CD000399-sec-0070"> <h5 class="title">Outcomes 1.10.2 and 1.11.2: Neurodevelopmental outcomes in infants with CDH</h5> <p>Survivors with CDH (from the <a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997</a> study) had comparable neurodevelopmental outcomes at follow‐up. Mean BSID MDI among controls was 73.6 (SD 18) and PDI was 77.2 (SD 14.4); among iNO‐treated infants, mean MDI was 69.1 (SD 17) and PDI was 75.8 (SD 25.8). Both control infants and iNO infants had a high rate of sensorineural hearing loss (4/14 control infants vs 3/8 iNO infants) (<a href="./references#CD000399-fig-0013" title="">Analysis 1.10</a>.2). </p> </section> </section> <section id="CD000399-sec-0071"> <h4 class="title">Comparison 2. iNO started for moderate compared with severe disease criteria</h4> <p>All five trials included in this group all showed no incremental benefit for death or requirement for ECMO when iNO was started earlier. </p> <section id="CD000399-sec-0072"> <h5 class="title">Outcome 2.1: Death or use of ECMO</h5> <p>The RR of death or ECMO was 0.88 (95% CI 0.62 to 1.27; five studies, 495 infants; RD ‐0.02, 95% CI ‐0.09 to 0.04). On sensitivity analysis, when data from Barefield and Cornfield were excluded, leaving only the results of Konduri, Gonzalez and Sadiq, review authors found no effect on the conclusion of effect (RR 0.83, 95% CI 0.54 to 1.2) (<a href="./references#CD000399-fig-0017" title="">Analysis 2.1</a>). </p> </section> <section id="CD000399-sec-0073"> <h5 class="title">Outcome 2.2: Death before hospital discharge</h5> <p>The RR of death with earlier treatment was 0.69 (95% CI 0.38 to 1.26; five studies, 495 infants; RD ‐0.03, 95% CI ‐0.08 to 0.02). On sensitivity analysis, we found no impact on the conclusion of no effect (RR 0.70, 95% CI 0.34 to 1.43) (<a href="./references#CD000399-fig-0018" title="">Analysis 2.2</a>). </p> </section> <section id="CD000399-sec-0074"> <h5 class="title">Outcome 2.3: Use of ECMO before hospital discharge</h5> <p>Four studies reported the requirement for ECMO (ECMO was not available for infants during <a href="./references#CD000399-bbs2-0007" title="GonzalezA , FabresJ , D'ApremontI , UrcelayG , AvacaM , GandolfiC , et al. Randomized controlled trial of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension. Journal of Perinatology2010;30(6):420‐4. ">Gonzalez 2010</a>). The RR for needing ECMO was 1.01 (95% CI 0.66 to 1.54; four studies, 439 infants; RD 0.00, 95% CI ‐0.06 to 0.06). On sensitivity analysis, we found that the RR for needing ECMO, after studies at higher risk of bias were excluded, was 0.90 (95% CI 0.52 to 1.58) (<a href="./references#CD000399-fig-0019" title="">Analysis 2.3</a>). </p> </section> <section id="CD000399-sec-0075"> <h5 class="title">Outcome 2.4: Progression to severe disease criteria</h5> <p>Treatment at lower disease severity appears to prevent progression to severe disease (i.e. fewer iNO participants progressed to satisfying rescue or severe disease criteria compared with control infants; RR 0.66, 95% CI 0.55 to 0.79; six studies, 512 infants; RD ‐0.20, 95% CI ‐0.28 to ‐0.12). On sensitivity analysis, we found that the RR was 0.59 (95% CI 0.48 to 0.74) (<a href="./references#CD000399-fig-0020" title="">Analysis 2.4</a>). </p> </section> <section id="CD000399-sec-0076"> <h5 class="title">Outcome 2.5: Chronic lung disease</h5> <p><a href="./references#CD000399-bbs2-0007" title="GonzalezA , FabresJ , D'ApremontI , UrcelayG , AvacaM , GandolfiC , et al. Randomized controlled trial of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension. Journal of Perinatology2010;30(6):420‐4. ">Gonzalez 2010</a>, <a href="./references#CD000399-bbs2-0010" title="KonduriGG , SolimanoA , SokolGM , SingerJ , EhrenkranzRA , SinghalN , et al. Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near‐term newborn infants with hypoxic respiratory failure. Pediatrics2004;113(3 Pt 1):559‐64. KonduriGG , VohrB , RobertsonC , SokolGM , SolimanoA , SingerJ , et al. Early inhaled nitric oxide therapy for term and near‐term newborn infants with hypoxic respiratory failure: neurodevelopmental follow‐up. Journal of Pediatrics2007;150(3):235‐40.e1. ">Konduri 2004</a> and <a href="./references#CD000399-bbs2-0016" title="SadiqFH , Illinois Multicenter Trial. Treatment of persistent pulmonary hypertension of the newborn with nitric oxide: a randomized trial. Pediatric Research1998;43:192A. SadiqHF , MantychG , BenawraRS , DevaskarUP , HockerJR . Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. Journal of Perinatology2003;23:98‐103. ">Sadiq 1998</a> reported frequency of requiring oxygen at 28 days of age. Early iNO confers no advantage over late iNO for this outcome (RR 0.91, 95% CI 0.54 to 1.53; three studies, 437 infants; RD ‐0.01, 95% CI ‐0.07 to 0.05). </p> </section> <section id="CD000399-sec-0077"> <h5 class="title">Outcomes 2.6 to 2.8: Neurodevelopmental outcomes</h5> <p>One study reported longer‐term neurodevelopmental outcomes (<a href="./references#CD000399-bbs2-0010" title="KonduriGG , SolimanoA , SokolGM , SingerJ , EhrenkranzRA , SinghalN , et al. Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near‐term newborn infants with hypoxic respiratory failure. Pediatrics2004;113(3 Pt 1):559‐64. KonduriGG , VohrB , RobertsonC , SokolGM , SolimanoA , SingerJ , et al. Early inhaled nitric oxide therapy for term and near‐term newborn infants with hypoxic respiratory failure: neurodevelopmental follow‐up. Journal of Pediatrics2007;150(3):235‐40.e1. ">Konduri 2004</a>). Analysis revealed no difference in frequency of neurological impairment or developmental delay at 18 to 24 months of age (<a href="./references#CD000399-fig-0022" title="">Analysis 2.6</a>), hearing loss requiring amplification (<a href="./references#CD000399-fig-0023" title="">Analysis 2.7</a>), nor grades of cerebral palsy (<a href="./references#CD000399-fig-0024" title="">Analysis 2.8</a>). Investigators showed no difference in severe CP but a lower BSID PDI score at 18 months among infants who received iNO early. </p> </section> <section id="CD000399-sec-0078"> <h5 class="title">Other possibly important outcomes</h5> <p><a href="./references#CD000399-bbs2-0007" title="GonzalezA , FabresJ , D'ApremontI , UrcelayG , AvacaM , GandolfiC , et al. Randomized controlled trial of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension. Journal of Perinatology2010;30(6):420‐4. ">Gonzalez 2010</a>, <a href="./references#CD000399-bbs2-0010" title="KonduriGG , SolimanoA , SokolGM , SingerJ , EhrenkranzRA , SinghalN , et al. Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near‐term newborn infants with hypoxic respiratory failure. Pediatrics2004;113(3 Pt 1):559‐64. KonduriGG , VohrB , RobertsonC , SokolGM , SolimanoA , SingerJ , et al. Early inhaled nitric oxide therapy for term and near‐term newborn infants with hypoxic respiratory failure: neurodevelopmental follow‐up. Journal of Pediatrics2007;150(3):235‐40.e1. ">Konduri 2004</a> and <a href="./references#CD000399-bbs2-0016" title="SadiqFH , Illinois Multicenter Trial. Treatment of persistent pulmonary hypertension of the newborn with nitric oxide: a randomized trial. Pediatric Research1998;43:192A. SadiqHF , MantychG , BenawraRS , DevaskarUP , HockerJR . Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. Journal of Perinatology2003;23:98‐103. ">Sadiq 1998</a> reported duration of mechanical ventilation and duration of oxygen therapy in the two groups. Konduri and Sadiq also reported duration of hospitalisation. Gonzalez reported outcomes as median and range, Konduri as median and interquartile range and Sadiq as mean and standard deviation. Therefore, meta‐analysis cannot be performed, but we have tabulated the results (<a href="#CD000399-tbl-0003">Table 1</a>). </p> <div class="table" id="CD000399-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Additional important outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ventilator days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gonzalez</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early iNO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 6, range 3‐28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 11.5, range 5‐90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late iNO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 8, range 4‐37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 18, range 6‐142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Konduri</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early iNO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 8, IQR 6‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 13, IQR 9‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 17, IQR 12‐22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late iNO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 8, IQR 6‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 13, IQR 9‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 18, IQR 12‐30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Sadiq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early iNO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 8,7, SD 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 14, SD 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 21, SD 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late iNO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 10, SD 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 18, SD 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 21, SD 11</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IQR: interquartile range; SD: standard deviation.</p> </div> </div> </section> </section> <section id="CD000399-sec-0079"> <h4 class="title">Comparison 3. iNO versus high‐frequency ventilation in infants with hypoxic respiratory failure </h4> <p>Only one study compared iNO versus high‐frequency ventilation. <a href="./references#CD000399-bbs2-0009" title="KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariE , ClarkRH , et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency ventilation in severe persistent pulmonary hypertension of the newborn. Pediatric Research1996;39:222A. KinsellaJP , TruogWE , WalshWF , GoldbergRN , BancalariEE , MayockDE , et al. Randomized, multicenter trial of inhaled nitric oxide and high‐frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. Journal of Pediatrics1997;131:55‐62. ">Kinsella 1997</a> found that 23% of infants treated with high‐frequency ventilation compared with 28% treated with iNO had a successful response, defined as PaO<sub>2</sub> greater than 60 mmHg. After cross‐over, 21% of 75 infants with high‐frequency ventilation failure responded to iNO, whereas 14% of 77 infants with iNO failure responded to high‐frequency ventilation (not significant). This study demonstrated that response to iNO was equivalent to response to high‐frequency ventilation among near‐term infants with hypoxic respiratory failure. Study authors evaluated infants who failed to respond to either therapy singly (n = 125) and found that 32% responded to the combination. Study authors concluded that the combination of high‐frequency ventilation and iNO was the most effective therapy for infants who failed to respond to either treatment alone. This study suggests that use of high‐frequency ventilation may be valuable in establishing adequate lung volumes in such a way that iNO therapy may then be efficacious. </p> <p>As all infants were eligible to receive iNO during preparation of the protocol, this study is not informative for the outcome of death or ECMO. As this is the only study included in this group, we have not performed any meta‐analysis. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000399-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000399-sec-0080"></div> <section id="CD000399-sec-0081"> <h3 class="title" id="CD000399-sec-0081">Main results</h3> <p>First, use of inhaled nitric oxide (iNO) at doses of 10 to 80 ppm is supported by studies that enrolled near‐term, hypoxic, mechanically ventilated neonates with an oxygenation index (OI) of 25 or greater, or partial pressure of arterial oxygen (PaO<sub>2</sub>) less than 100 mmHg in 100% oxygen. Use of iNO in these circumstances decreases the need for extracorporeal membrane oxygenation (ECMO). All but one of the trials that compared iNO versus no iNO had ECMO available for participants who were failing, and no effect on mortality was evident. One very small trial from China (<a href="./references#CD000399-bbs2-0011" title="LiuCQ , MaL , TangLM , HeXJ , WeiSF , WangSX , et al. A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2008;46(3):224‐8. ">Liu 2008</a>), which had no ECMO available, showed a small reduction in mortality, which may have been due to chance. ECMO is invasive and expensive and is associated with clinically important complications. Therefore, a reduction in ECMO requirement with less invasive and safer treatment provides benefit for patients. However, reviewed trials showed significant differences with respect to the use of other therapies, such as high‐frequency ventilation or surfactant. <a href="./references#CD000399-bbs2-0013" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full‐term and nearly full term infants with hypoxic respiratory failure. New England Journal of Medicine1997;336:597‐604. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1996,</a><a href="./references#CD000399-bbs2-0014" title="The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics1997;99:838‐45. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 1997,</a><a href="./references#CD000399-bbs2-0006" title="DayRW , LynchJM . Acute hemodynamic and blood gas effects of inhaled nitric oxide in newborns with lung disease and pulmonary hypertension. Pediatric Research1996;39:330A. DayRW , LynchJM , WhiteKS , WardRM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics1996;98:698‐705. ">Day 1996</a> and <a href="./references#CD000399-bbs2-0017" title="EllingtonM , O'ReillyD , AllredEN , McCormickMC , WesselDL , KourembanasS . Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics2001;107:1351‐6. WesselD , AdatiaI , ThompsonJ , KaneJ , VanMarterL , StarkA , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research1996;39:252A. WesselDL , AdatiaI , VanMarterLJ , ThompsonJE , KaneJW , StarkAR , et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics1997;100(5):e7. ">Wessel 1996</a> allowed both treatments, <a href="./references#CD000399-bbs2-0003" title="ClarkRH , KeuserTJ , WalkerMW , SouthgateMS , HuckabyJL , PerezJA , et al. for the Clinical Inhaled Nitric Oxide Research Group. Low‐dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. New England Journal of Medicine2000;342:469‐74. ">Clark 2000</a> "encouraged" both treatments, whereas others proscribed such management or excluded infants who received such treatments (<a href="./references#CD000399-bbs2-0001" title="BarefieldES , KarkeVA , PhillipsJB , CarloWA . Inhaled nitric oxide in term infants with hypoxemic respiratory failure. Journal of Pediatrics1996;129:279‐86. BarefieldES , KarkeVA , PhillipsJB , CarloWA . Randomized, controlled trial of inhaled NO in ECMO candidates. Pediatric Research1995;37:195A. ">Barefield 1996</a> proscribed both; <a href="./references#CD000399-bbs2-0015" title="RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336:605‐10. RobertsJDJr , FinemanJ , MorinFCIII , ShaulPW , RimarS , SchreiberMD , et al. Inhaled nitric oxide gas improves oxygenation in PPHN. Pediatric Research1996;39:241A. ">Roberts 1996</a> disallowed high‐frequency ventilation; <a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a> excluded infants who received surfactant therapy and did not allow concurrent high‐frequency ventilation). </p> <p>Second, studies that enrolled infants at moderate disease severity and randomised them to immediate iNO, or to iNO only if their condition deteriorated, showed no incremental benefit of giving iNO earlier, even if infants receiving earlier iNO were less likely to experience a deterioration in their oxygenation. </p> <p>Third, the <a href="./references#CD000399-bbs2-0043" title="Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near‐term infants: neurodevelopmental follow‐up of the neonatal inhaled nitric oxide study group (NINOS). Journal of Pediatrics2000;136:611‐7. ">Ninos 2000</a> publication provides reassuring information regarding long‐term neurodevelopmental outcomes and demonstrates that infants who receive iNO are not at increased risk of neurodevelopmental sequelae, consistent with the observations of Rosenberg and coworkers (<a href="./references#CD000399-bbs2-0050" title="RosenbergAA , KennaughJM , MorelandSG , FashawLM , HaleKA , TorielliFM , et al. Longitudinal follow‐up of a cohort of newborn infants treated with inhaled nitric oxide for persistent pulmonary hypertension. Journal of Pediatrics1997;131:70‐5. ">Rosenberg 1997</a>), and did not experience increased postdischarge pulmonary complications, consistent with the report of Dobyns and coworkers (<a href="./references#CD000399-bbs2-0025" title="DobynsEL , GriebelJ , KinsellaJP , AbmanSH , AccursoFJ . Infant lung function after inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn. Pediatric Pulmonology1999;28:24‐30. ">Dobyns 1999</a>). </p> <p>Fourth, clinical or echocardiographic evidence of pulmonary hypertension was not universally present in all reported trials; therefore, use of iNO should be considered for near‐term infants with hypoxic respiratory failure, with or without clear evidence of pulmonary hypertension. Inhaled NO can improve ventilation/perfusion mismatching and may improve oxygenation by this mechanism in infants without documented pulmonary hypertension. </p> </section> <section id="CD000399-sec-0082"> <h3 class="title" id="CD000399-sec-0082">Limits/toxicity issues</h3> <p>Nitric oxide reacts with oxygen to form nitrogen dioxide (NO<sub>2</sub>). Both NO and NO<sub>2</sub> are toxic, causing death in dogs at concentrations between 0.1% and 2% due to methaemoglobinaemia, hypoxaemia and pulmonary edema (<a href="./references#CD000399-bbs2-0031" title="GreenbaumR , BayJ , HargreavesMD , KainML , KelmanGR , NunnJF , et al. Effects of higher oxides of nitrogen on the anaesthetized dog. British Journal of Anaesthesia1967;39:393‐404. ">Greenbaum 1967</a>). In humans, exposure to 2.3 ppm NO<sub>2</sub> for five hours produced a 14% decrease in serum glutathione peroxidase activity and a 22% decrease in alveolar permeability 11 hours after the start of exposure, suggesting that even very low concentrations of NO<sub>2</sub> may produce a delayed response (<a href="./references#CD000399-bbs2-0046" title="RasmussenTR , KjaergaardSK , TarpU , PedersenOF . Delayed effects of NO2 exposure on alveolar permeability and glutathione peroxidase in healthy humans. American Review of Respiratory Disease1992;146:654‐9. ">Rasmussen 1992</a>). Occupational health guidelines set 25 ppm as the limit for eight hours/day NO exposure in the workplace, and 3 ppm (measured as the time‐weighted average) as the limit for NO<sub>2</sub> (<a href="./references#CD000399-bbs2-0042" title="National Institute for Occupational Safety and Health. NIOSH recommendations for occupational safety and health standards. MMWR1988;37:21. ">MMWR 1988</a>). It has been demonstrated that using 80 ppm iNO in a neonatal ventilator with fraction of inspired oxygen (FiO<sub>2</sub>) of 0.9 could produce 5 ppm NO<sub>2</sub> in less than 20 seconds (<a href="./references#CD000399-bbs2-0022" title="BouchetM , RenaudinMH , RaveauC , Mercier JC DehanM , ZupanV . Safety requirement for use of inhaled nitric oxide in neonates. Lancet1993;341:968‐9. ">Bouchet 1993</a>). Ongoing monitoring of inhaled gas for NO<sub>2</sub> is therefore mandatory. </p> <p>The condition of infants receiving iNO, even those who have not demonstrated a positive response, may deteriorate when iNO is discontinued. Davidson and coworkers (<a href="./references#CD000399-bbs2-0024" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. Pediatrics1999;104:231‐6. ">Davidson 1999</a>) reviewed the results of their previous trial (<a href="./references#CD000399-bbs2-0005" title="DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double‐masked, placebo‐controlled, dose‐response, multicenter study. Pediatrics1998;101:325‐34. DavidsonD , BarefieldES , KattwinkelJ , DudellG , DamaskM , StraubeR , et al. I‐NO/PPHN Study Group. A double masked, randomized, placebo controlled, dose response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research1997;41:144A (abstract). ">Davidson 1997</a>) and reported a 42 ± 101% increase in OI when iNO was withdrawn from participants who did not demonstrate a positive response to iNO. They reported that minimising the iNO dose to 1 ppm before discontinuation was associated with the least deterioration, so it appears that this practice should be followed for infants who are being weaned from iNO, regardless of their initial response. </p> <p>Methaemoglobin levels must also be carefully monitored, and significant methaemoglobinaemia has been reported after accidental overdose of a neonate with &gt; 135 ppm of iNO (<a href="./references#CD000399-bbs2-0033" title="HealCA , SpencerSA . Methaemoglobinaemia with high‐dose nitric oxide administration. Acta Paediatrica1995;84:1318‐9. ">Heal 1995</a>). Long‐term treatment (up to 23 days for a newborn, 53 days for an adult) has not been shown to increase toxicity. When NO reacts with superoxide, peroxynitrite is rapidly formed, and this can result in membrane lipid peroxidation (<a href="./references#CD000399-bbs2-0021" title="BeckmanJS , BeckmanTW , ChenJ , MarshallPA , FreemanBA . Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxides. Proceedings of the National Academy of Sciences of the United States of America1990;87:1620‐4. ">Beckman 1990</a>). No information is available to date with respect to the actual formation of such peroxynitrites in human patients receiving iNO, but the potential remains for resultant tissue injury, especially in the lung, with damage to surfactant and its related proteins (<a href="./references#CD000399-bbs2-0032" title="HaddadIY , IschiropoulosH , HolmBA , BeckmanJS , BakerJR , MatalonS . Mechanisms of peroxynitrite‐induced injury to pulmonary surfactants. American Journal of Physiology1993;265:L555‐64. ">Haddad 1993</a>). NO inhibits platelet aggregation and adhesion and in this way plays an important role in vascular homeostasis (<a href="./references#CD000399-bbs2-0045" title="RadomskiMW , MoncadaS . Regulation of vascular homeostasis by nitric oxide. Thrombosis and Haemostasis1993;70:36‐41. ">Radomski 1993</a>). Although it is believed that iNO does not exert systemic effects because of the previously mentioned interaction with haemoglobin, Hogman and coworkers have reported increased bleeding times in rabbits and humans exposed to 30 ppm of iNO (<a href="./references#CD000399-bbs2-0036" title="HogmanM , FrostellC , ArnbergH , HedenstiermaG . Bleeding time prolongation and NO inhalation. Lancet1993;341:1664‐5. ">Hogman 1993</a>; <a href="./references#CD000399-bbs2-0037" title="HogmanM , FrostellC , ArnbergH , SandhagenB , HedenstiernaG . Prolonged bleeding time during nitric oxide inhalation in the rabbit. Acta Physiologica Scandinavica1994;151:125. ">Hogman 1994</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000399-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update." data-id="CD000399-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000399-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000399-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 1 Death or use of ECMO." data-id="CD000399-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 1 Death or use of ECMO.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 2 Death before hospital discharge." data-id="CD000399-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 2 Death before hospital discharge.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 3 Use of ECMO before hospital discharge." data-id="CD000399-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 3 Use of ECMO before hospital discharge.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 4 Failure to improve oxygenation (PaO2)." data-id="CD000399-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 4 Failure to improve oxygenation (PaO<sub>2</sub>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 5 Oxygenation index 30 to 60 minutes after treatment." data-id="CD000399-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 5 Oxygenation index 30 to 60 minutes after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 6 PaO2 30 to 60 minutes after treatment." data-id="CD000399-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 6 PaO<sub>2</sub> 30 to 60 minutes after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 7 Change in oxygenation index after treatment." data-id="CD000399-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 7 Change in oxygenation index after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 8 Change in PaO2 after treatment." data-id="CD000399-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 8 Change in PaO<sub>2</sub> after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 9 Neurodevelopmental disability at 18 to 24 months among survivors." data-id="CD000399-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 9 Neurodevelopmental disability at 18 to 24 months among survivors. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 10 Hearing impairment in at least 1 ear among survivors." data-id="CD000399-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 10 Hearing impairment in at least 1 ear among survivors. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 11 Cerebral palsy among survivors." data-id="CD000399-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 11 Cerebral palsy among survivors.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 12 BSID MDI &gt; 2 SD below the mean." data-id="CD000399-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 12 BSID MDI &gt; 2 SD below the mean.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inhaled NO versus control, Outcome 13 BSID PDI &gt; 2 SD below the mean." data-id="CD000399-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Inhaled NO versus control, Outcome 13 BSID PDI &gt; 2 SD below the mean.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 1 Death or use of ECMO." data-id="CD000399-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 1 Death or use of ECMO. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 2 Death before hospital discharge." data-id="CD000399-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 2 Death before hospital discharge. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 3 Use of ECMO before hospital discharge." data-id="CD000399-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 3 Use of ECMO before hospital discharge. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 4 Progression to severe disease criteria." data-id="CD000399-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 4 Progression to severe disease criteria. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 5 Chronic lung disease." data-id="CD000399-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 5 Chronic lung disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 6 Neurodevelopmental disability at 18 to 24 months among survivors." data-id="CD000399-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 6 Neurodevelopmental disability at 18 to 24 months among survivors. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 7 Hearing impairment among survivors." data-id="CD000399-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 7 Hearing impairment among survivors. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000399-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/urn:x-wiley:14651858:media:CD000399:CD000399-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_t/tCD000399-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 8 Cerebral palsy among survivors." data-id="CD000399-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Inhaled NO at moderate compared with severe criteria for illness severity, Outcome 8 Cerebral palsy among survivors. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/media/CDSR/CD000399/image_n/nCD000399-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000399-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Inhaled NO compared with control for respiratory failure in infants born at or near term</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Inhaled NO compared with control for respiratory failure in infants born at or near term</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> respiratory failure in infants born at or near term<br/> <b>Setting:</b> neonatal intensive care units<br/> <b>Intervention:</b> inhaled NO<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inhaled NO</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death or use of ECMO; studies that did not allow back‐up use of iNO in controls</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/> (0.57 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>859<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>540 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>356 per 1000<br/> (308 to 416) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death or use of ECMO; infants with diaphragmatic hernia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.09<br/> (0.95 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>870 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>948 per 1000<br/> (826 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death before hospital discharge; studies that did not allow back‐up use of iNO in controls </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.60 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>860<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/> (72 to 157) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death before hospital discharge; infants with diaphragmatic hernia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.20<br/> (0.74 to 1.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>391 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1000<br/> (290 to 767) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Use of ECMO before hospital discharge; studies that did not allow back‐up use of iNO in controls </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.60<br/> (0.50 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>815<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>514 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1000<br/> (257 to 365) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Use of ECMO before hospital discharge; infants with diaphragmatic hernia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.27<br/> (1.00 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>674 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>856 per 1000<br/> (674 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurodevelopmental disability at 18 to 24 months among survivors</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.66 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>301<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1000<br/> (175 to 382) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; OR: odds ratio; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to the estimate of effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Small numbers of participants studied. </p> <p><sup>b</sup>Subgroup of participants from only 2 trials evaluated. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Inhaled NO compared with control for respiratory failure in infants born at or near term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000399-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Inhaled NO at moderate compared with severe criteria for illness severity in respiratory failure among infants born at or near term</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Inhaled NO at moderate compared with severe criteria for illness severity in respiratory failure among infants born at or near term</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants born at or near term in respiratory failure<br/> <b>Setting:</b> neonatal intensive care units<br/> <b>Intervention:</b> inhaled NO at moderate criteria for illness severity (earlier iNO)<br/> <b>Comparison:</b> inhaled NO at severe criteria for illness severity (later iNO) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inhaled NO at severe criteria for illness severity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Inhaled NO at moderate criteria for illness severity</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death or requirement for ECMO</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.62 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>495<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000<br/> (119 to 244) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death before hospital discharge</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.69<br/> (0.38 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>495<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000<br/> (38 to 126) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Use of ECMO before hospital discharge</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/> (0.66 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>439<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>146 per 1000<br/> (95 to 222) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression to severe criteria</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/> (0.55 to 0.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>512<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>595 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>392 per 1000<br/> (327 to 470) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurodevelopmental disability at 18 to 24 months among survivors</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.74 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>234<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000<br/> (183 to 431) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; OR: odds ratio; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to the estimate of effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Highly variable risk ratio. </p> <p><sup>b</sup>Very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Inhaled NO at moderate compared with severe criteria for illness severity in respiratory failure among infants born at or near term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000399-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Additional important outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ventilator days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gonzalez</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early iNO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 6, range 3‐28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 11.5, range 5‐90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late iNO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 8, range 4‐37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 18, range 6‐142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Konduri</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early iNO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 8, IQR 6‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 13, IQR 9‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 17, IQR 12‐22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late iNO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 8, IQR 6‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 13, IQR 9‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 18, IQR 12‐30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Sadiq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early iNO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 8,7, SD 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 14, SD 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 21, SD 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late iNO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 10, SD 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 18, SD 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 21, SD 11</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>IQR: interquartile range; SD: standard deviation.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Additional important outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/full#CD000399-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000399-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Inhaled NO versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death or use of ECMO <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Death or use of ECMO; studies that did not allow back‐up use of iNO in controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.57, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Death or use of ECMO; studies that allowed back‐up use of iNO in controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.34, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Death or use of ECMO; infants with diaphragmatic hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.95, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Death; studies that did not allow back‐up use of iNO in controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.60, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Death; studies that allowed back‐up use of iNO in controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.34, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Death; infants with diaphragmatic hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.74, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Use of ECMO before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Use of ECMO before hospital discharge; studies that did not allow back‐up use of iNO in controls </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.50, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Use of ECMO before hospital discharge; infants with diaphragmatic hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.00, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Failure to improve oxygenation (PaO<sub>2</sub>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Failure to improve PaO2; studies that did not allow back‐up use of iNO in controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Failure to improve PaO2; infants with diaphragmatic hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Oxygenation index 30 to 60 minutes after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.59 [‐11.53, ‐5.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 OI 30 to 60 minutes after treatment; studies that did not allow back‐up use of iNO in controls </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.45 [‐11.42, ‐5.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 OI 30 to 60 minutes after treatment; infants with diaphragmatic hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.1 [‐38.04, 5.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PaO<sub>2</sub> 30 to 60 minutes after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>32.62 [23.56, 41.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 PaO2 after 30 to 60 minutes; studies that did not allow back‐up use of iNO in controls </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>43.91 [32.30, 55.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 PaO2 after 30 to 60 minutes; infants with diaphragmatic hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.10 [0.64, 29.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in oxygenation index after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.61 [‐18.53, ‐8.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Change in OI; studies that did not allow back‐up use of iNO in controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.1 [‐20.52, ‐9.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Change in OI; infants with diaphragmatic hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.7 [‐18.39, 4.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change in PaO<sub>2</sub> after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.27 [7.18, 23.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Change in PaO2; studies that did not allow back‐up use of iNO in controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>50.4 [32.14, 68.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Change in PaO2; infants with diaphragmatic hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.70 [‐2.32, 15.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Neurodevelopmental disability at 18 to 24 months among survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.66, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Hearing impairment in at least 1 ear among survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.72, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Hearing impairment among survivors; studies that did not allow back‐up use of iNO in controls </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.71, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Hearing impairment among survivors; infants with diaphragmatic hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.39, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Cerebral palsy among survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.62, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Cerebral palsy among survivors; studies that did not allow back‐up use of iNO in controls </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.49, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Cerebral palsy among survivors; infants with diaphragmatic hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.33 [0.45, 154.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 BSID MDI &gt; 2 SD below the mean <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.38, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 BSID PDI &gt; 2 SD below the mean <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.25, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Inhaled NO versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000399-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Inhaled NO at moderate compared with severe criteria for illness severity</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death or use of ECMO <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.62, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.38, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Use of ECMO before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.66, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Progression to severe disease criteria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.55, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Chronic lung disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.54, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Neurodevelopmental disability at 18 to 24 months among survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.74, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hearing impairment among survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.03, 2.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Cerebral palsy among survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.53, 3.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Inhaled NO at moderate compared with severe criteria for illness severity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000399.pub3/references#CD000399-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000399.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000399-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000399-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD000399-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD000399-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000399\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000399\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000399\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000399\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000399\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000399.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000399.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000399.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000399.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000399.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729649650"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000399.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729649653"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000399.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee210e8c09377',t:'MTc0MDcyOTY0OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 